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ABSTRACT OF THE DISSERTATION
The Molecular Basis of Antibody Neutralization of Hepatitis C Virus
by
Michelle Catherine Sabo
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2013
Professor Michael Diamond, Chairperson

Hepatitis C virus (HCV) is positive strand, blood-borne, hepatotropic RNA virus that causes
chronic infection in ~170 million people worldwide and is the leading cause of liver transplantation
in the United States. HCV entry and attachment is mediated by the envelope protein E2 through
interaction with several cellular receptors including CD81, scavenger receptor B1 (SRB-1),
claudin-1, and occludin, although the exact mechanism by which these receptors facilitate
infection remains unclear, largely due to the absence of a structural model of E2. The production
of neutralizing antibodies against E2 is thought to be important for controlling HCV infection, likely
by blocking virus interaction with these receptors. To better understand the structural and
molecular basis of antibody neutralization of HCV, which could be used to inform novel
therapeutic or vaccine approaches, we generated a panel of 78 monoclonal antibodies (MAbs)
against the E2 protein from HCV genotypes 1 and 2 and assessed their neutralizing activity in
vitro. Using this approach and by performing mechanistic studies, we identified three neutralizing
MAbs, H77.16, H77.39, and J6.36, that inhibit infection at a post-attachment step. Using a yeast
display library of E2 protein variants, we mapped the critical binding residues of these MAbs to
distinct regions of the E2 protein: H77.16 binds within the HVR1 and to a conserved CD81
binding region ~125 amino acid residues C-terminal to the HVR1; H77.39 binds to conserved
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residues upstream of the hypervariable region (HVR1); and J6.36 binds to amino acid residues

	
  

x	
  

within HVR1 as well a site ~150 amino acids C-terminal to HVR1. Receptor-binding inhibition
studies using E2 demonstrated that H77.16 potently inhibits binding to SR-B1, H77.39 potently
inhibits binding to SR-B1 and CD81, and J6.36 potently inhibits binding to SR-B1 and modestly
inhibits binding to CD81. Further mechanistic studies demonstrated that MAb-mediated
neutralization could be enhanced by increases in pre-incubation temperature and time and that
these results were likely due to altered epitope exposure on the viral surface. Together, these
data provide new insight into the mechanisms by which antibodies neutralize infection of HCV.
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Chapter 1
Introduction

1

ABSTRACT
Hepatitis C virus (HCV) is significant cause of morbidity and mortality worldwide. Approximately
80% of exposed individuals develop chronic disease, which is associated with an increased risk
of cirrhosis and hepatocellular carcinoma. Despite the financial and emotional burden of this
disease, there is no vaccine and treatment options remain limited.

The role of the immune

response in protection from HCV remains unclear, although vaccination and passive transfer
studies suggest that antibodies to the HCV envelope 2 (E2) protein prevent infection. This
chapter will provide an introduction to HCV, the mechanisms of monoclonal antibody (MAb)
neutralization, and what is known about the antibody response to HCV.

2

Epidemiology and importance of human disease
Hepatitis C virus (HCV) is a hepatotropic RNA virus that infects ~170 million people
worldwide (18) and is the leading cause of liver transplantation in the United States (3). HCV is a
blood borne pathogen, and in the developed world is primarily transmitted by injection drug use.
In developing countries, unsafe therapeutic injections and transfusion with contaminated blood
are the main sources of HCV transmission (143). The first six months of HCV infection is
considered the period of “acute,” often asymptomatic, infection.

During this time, ~ 20% of

individuals will spontaneously clear infection, whereas the remaining ~ 80% will progress to
chronic disease(66), which is associated with an increased risk of cirrhosis and hepatocellular
carcinoma (18). Until recently, the only treatment available was a combination of ribavirin and
pegylated interferon-α, which had a response rate of ~50%, depending on the genotype of
infection (45). Recent addition of NS3/4A protease inhibitors (boceprevir and telaprevir) improved
response rates in clinical trials, although an increase in side effects also was observed (4, 67,
130, 169). Currently no vaccine is available, the development of which could be invaluable as a
prophylactic or therapeutic in high-risk populations or resource-poor countries (146).
HCV is divided into seven genotypes, which share ~30% nucleotide identity. These
genotypes are further divided into subtypes, which share ~20% nucleotide identity (7, 53, 145).
Furthermore, quasispecies develop in infected hosts as a result of immune pressure, a highly
error prone polymerase, and high viral burden (22). Distribution of genotypes is largely
geographical, with genotypes 1 and 2 being the most prevalent in the United States(7). Response
rates to treatment were previously highly genotype dependent, with genotype 1 being the least
responsive to therapy(45), although the new NS3/4A protease inhibitors have dramatically
improve response rates in genotype 1 infected patients(4, 67, 130, 169).

Virus structure, replication and assembly
HCV is a 9.6kb, positive stranded RNA virus in the family Flaviviridae, in the genus
Hepacivirus (86). HCV is comprised of three structural proteins (core, E1, E2) p7, an ion channel,
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and six non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) (88).
The nonstructural proteins perform many functions, including (i) combining to serve as viral
proteases (NS2/NS3, NS3/NS4A), and a helicase (NS3/NS4A); (ii) inhibiting the host immune
response (NS3/NS4A, NS5A); (iii) formation of the replication complex in the ER (NS4B); (iv)
facilitation of particle replication and assembly (NS5A)(73, 104, 133, 150). The RNA polymerase,
NS5B, lacks intrinsic proofreading activity and is thus highly error-prone(104).
HCV virus enters cells via endocytosis through clathrin-coated pits (100) and fuses with
the endosomal membrane in a pH dependent manner to release the viral genome into the
cytoplasm (13, 17, 25, 64, 79, 80, 153). Several attachment factors have been implicated in HCV
entry (see below). After viral fusion, translation of the HCV polyprotein occurs via an internal
ribosomal entry sequence (IRES) located in the 5’ non-translated region (NTR). The HCV
polyprotein is cleaved by both host and viral proteases (104), and the viral non-structural proteins
form a replication complex in association with the endoplasmic reticulum (ER) and lipid droplets
(108). With the development of an infectious HCV system in tissue culture, the dynamics of viral
particle assembly and release are beginning to be studied.
A precise structural understanding of the mature virion remains elusive, largely due to the
lack of envelope protein crystal structures as well as the difficulty in producing sufficient quantities
of HCV virions for use in cryo-electron microscopy (cryo-EM). One study overcame the latter
limitation by using a highly efficient cell-culture adapted strain, which increased titers by ~ 100fold, combined this with density gradient ultracentrifugation to produce high titer viral stocks. Lowresolution cryo-EM revealed small, spherical particles of about 50 nm in diameter (50). The
range of particle sizes, (~31 to >100nm), as well as the average diameter, was consistent with
previous analyses of sera from infected patients (70, 85, 131) and cell culture infectious virus
(158, 166).

Analysis of the cryo-EM data suggests that the range of sizes corresponds to

differences in particle populations; smaller particles were non-enveloped and had limited
infectivity, particles with the highest infectivity were enveloped and fell into a mid-size range, and
rare populations of large particles were multivesicular and less infectious (50).
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Models of HCV Infection
For many years, the absence of an in vitro model for HCV has restricted the study of
HCV attachment and entry. Over the past decade, two models for studying HCV infection in vitro
have been developed: HCV pseudotyped particles (HCVpp) and a cell culture-derived HCV
(HCVcc) infectious clone. HCVpp are generated by co-transfection of expression constructs
containing the retroviral genes gag and pol, a marker gene (e.g. Luciferase or GFP), and HCV
envelope proteins E1 and E2, into 293T cells. The retroviral genes and marker genes are
packaged by the HCV envelope proteins and released into the cell supernatant; HCVpp are
capable of sustaining a single round of infection in hepatoma cells (11, 64, 155). The first fulllength infectious HCV clone that produced particles capable of full lifecycle infection was derived
from a Japanese patient with fulminant hepatitis (JFH-1 strain, genotype 2a)(87, 159). A chimeric
J6/JFH1 strain of virus, which replaces JFH-1 core to NS2 with J6 strain (genotype 2a) proteins,
produces higher titers of virus and is commonly used in laboratory research (reviewed in (6)).
Recently, chimeric viruses expressing structural proteins from genotypes 1, 3, 4, 5, 6 and 7 on a
JFH1 backbone with cell culture compensatory mutations have been described (52, 53, 68, 94,
126, 140, 164). Progress is also being made in the development of a system to study infection in
primary hepatocytes, although this system is still limited by a lack of long-term survival and
proliferation in culture (129).
To date, a high-throughput, readily tractable small animal model for HCV infection does
not exist. In one model, SCID mice are bred to transgenically express urokinase-type
plasminogen activator (uPA). Expression of uPA results in destruction of murine hepatocytes and
allows for engraftment of human hepatocytes, which can sustain HCV infection for ~4 weeks
(reviewed in (8). In another model, wild type (WT) mice were lethally irradiated and transplanted
with SCID bone marrow and subsequently engrafted with human hepatocytes and infected with
virus (65).

Although useful in assessing antivirals, both models require the use of

immunodeficient mice, thus precluding studies of the host immune response to HCV.
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Advances in the development of an immunologically intact mouse infectious model have
come with the identification of claudin-1(CLDN-1) (42) and occludin (OCLN) (128) as critical HCV
entry factors; expression of human versions CLDN-1, OCLN, CD81, and scavenger receptor B1
(SR-B1) rendered murine cell lines susceptible to infection(128). Further studies demonstrated
that species-specific tropism for human compared to murine cells is determined by expression of
human CD81 and human OCLN, but not SR-B1 and CLDN-1 (30, 128). Indeed, adenoviral
vectors expressing all four human receptors in immunocompetent mice allowed for entry, but not
replication, of cell culture HCV in immunologically intact mice (30). Adaptation of cell culture
derived HCV to murine CD81 also has allowed for entry into murine hepatocytes, although only
after expression of murine or human versions of SR-B1, CLDN-1 and OCLN, and replication
within these cells was not assessed (16).
The only natural animal model for HCV is the chimpanzee. Although chimpanzees are
susceptible to HCV, the cost and ethical considerations associated with these animals makes
studies costly and challenging. Additionally, unlike humans, only ~40% of chimpanzees progress
to chronic HCV, as opposed to ~80% of human subjects, and they do not develop liver disease
(54), making vaccination and therapeutic studies difficult to interpret.

Receptors, Attachment, and Entry
Despite intense study by multiple groups over the past few years, the precise mechanism
of viral attachment and entry remains unclear. Several receptors, including CD81, SR-B1, CLDN1, OCLN, glycosaminoglycans, and the low-density lipoprotein receptor (LDL-R), have been
suggested as important in HCV attachment and entry. The following paragraphs will review these
receptors and their function in HCV life cycle.

CD81
CD81 is a ubiquitously expressed membrane tetraspanin protein that is thought to
interact within a “tetraspanin web” to modulate cell signaling and changes in morphology
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associated with adhesion, synapse formation, fusion, endocytosis and exocytosis. The structure
of CD81 has a small extracellular loop between transmembrane domains 1 and 2, and a large
extracellular loop (LEL) between transmembrane domains 3 and 4 (reviewed in (82)).
Structurally, the LEL is thought to form a “mushroom” shape, with two helices, A and E, forming
the “stalk” of the mushroom, and three helices, B, C, and D, forming the head (74). Helices C
and D are the most divergent sequences in CD81, distinguishing human CD81 from other
tetraspanins and from CD81 found in other species (82).
In 1998, Abrignani’s group showed that recombinant, soluble HCV E2 (sE2) bound the
(LEL) of human CD81, providing the first description of an HCV receptor (127). Since the initial
publication, the ability of sE2 to bind to the LEL of human CD81 has been verified (39, 47, 48, 57,
63, 118, 136). Residue F186 on CD81 is an important residue in the LEL for mediating E2 binding
(15, 39, 47, 63), and several other residues (I181, I182, L185, W163, K171, E188, and D196)
have all been implicated in E2 binding (15, 39, 47). CD81 is necessary, but not sufficient, for viral
entry (13, 26), suggesting that other receptors participate in viral entry. Indeed, it has been
proposed that the kinetics of CD81 internalization are too slow to permit viral entry alone (15, 105,
123, 148), further substantiating that HCV infection requires multiple receptors and attachment
factors.

SR-B1
SR-B1 is a 509 amino acid transmembrane protein that is expressed in a variety of
tissues, including the liver, where it is found on nearly all cell types, including hepatocytes,
Kupffer cells and sinusoidal epithelium. Structurally, SR-B1 is composed of two transmembrane
domains that are bridged by a 407aa extracellular domain of unknown structure. The extracellular
domain contains 11 and 9 N-linked glycosylation sites in mice and humans, respectively, which
may be important in providing a negatively charged environment to assist with ligand recognition.
SR-B1 interacts with a variety of ligands, including low density lipoprotein (LDL), oxidized LDL,
acylated LDL, very low density lipoprotein (VLDL), and high density lipoprotein (HDL), and is
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thought to be particularly important for the uptake of cholesteryl esters and free cholesterol from
HDL (134).
SR-B1 has been shown to bind soluble, recombinant E2 (46, 95, 139), likely via the E2
hypervariable region 1 (HVR1) (46, 139). SR-B1 also may play a role in the enhancement of
HCV infection by HDL, although the mechanism for this phenomenon remains unknown (12, 34,
36, 156, 168). Recent data has shown that both the C-terminal cytoplasmic tail (35) as well as
the extracellular domain of SR-B1 are important in HCV entry (35, 168). Unlike CD81, HCV can
utilize both the murine and human SR-B1 receptor for entry (30, 128).

Claudin-1
CLDN-1 is a four transmembrane domain tight junction protein that is important in forming
a permeability barrier at the apical side of epithelial cells. CLDN-1 contains a large and small
extracellular loop (EC1 and EC2, respectively) (42, 141). CLDN-1 co-localizes with CD81, likely
via residues I32 and E48 in the EC1 (42, 59, 60), and is believed to act at a post-attachment step
(42, 77). Furthermore, inhibition of CD81, SR-B1 and CLDN-1 results in synergistic blockade of
infection as compared to inhibition of the individual receptors, suggesting that all three receptors
act in a coordinated manner to promote infection (77). Original reports suggested that CLDN-1
directly bound E1, E2 and E1-E2 (163), but these results have since been challenged (77).
Despite a lack of evidence for direct interaction with sE2, blockade of CLDN-1 with anti-CLDN-1
antibodies resulted in decreased binding of E2 and infectious virus to Huh7.5 cells (77),
suggesting that CLDN-1 may stabilize HCV interactions with other receptors.

Occludin
Like CLDN-1, OCLN is also a four transmembrane tight junction protein with two
extracellular loops (141). Occludin was the last receptor identified that appears to be required for
HCV entry, as co-transfection of CD81, SR-B1, CLDN-1 and OCLN rendered non-human and
non-hepatocyte

cell

lines

permissive

to

HCV
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infection.

Interestingly,

further

analysis

demonstrated that the species specificity of HCV was determined by human OCLN and CD81,
but not human SR-B1 and CLDN-1 (30, 103, 128); species specificity of OCLN has been
localized to residues A223 and A224 in the second extracellular loop (EC2) (103, 128). OCLN
does not appear to directly interact with sE2 (89), but does co-immunoprecipitate structural
proteins associated with infectious virus(90).

Other potential receptors
In addition to the four well-characterized receptors described above, additional receptors
and attachment factors have been suggested to play a role in HCV attachment and entry. These
receptors will be reviewed briefly below.
Heparan Sulfate. Heparan sulfate is an anionic glycosaminoglycan that is ubiquitously
expressed (14). E1 (10), E2 (9) and E1-E2 (154) have been suggested to bind heparin, and E2
binding has been localized to the HVR1, residues within the CD81 binding region (residues 480487 and 516-530) and residues 412-423 (10). In contrast to SR-B1 and CD81, inhibition studies
have shown that heparin blocks infection at a pre-attachment step (56, 93), leading to speculation
that heparan sulfate is involved in initial attachment to hepatocytes (21).
Low Density Lipoprotein Receptor. Although not one of the four “minimal” receptors
required for HCV infection of non-permissive cell lines, low-density lipoprotein receptor (LDL-R)
has also been implicated in HCV entry (reviewed in (21)). Recent studies have demonstrated that
knockdown of LDL-R reduces HCVcc infection in Huh7.5 cells, whereas over-expression
enhances infection (112).

Nonetheless, the precise role in attachment and entry remains

unknown, although it has been suggested that HCV may utilize LDL-R mediated endocytosis for
cell entry (1).
Epidermal Growth Factor Receptor. Recently, the Epidermal Growth Factor Receptor
(EGFR) was shown to be important HCV for entry. Although unable to bind E2 directly, EGFR
was vital for HCVcc infection at a post-binding step, likely by promoting CD81-CLDN-1
interactions, and/or promoting fusion via kinase signaling (93). This receptor, however, does not

9

limit species-specific infectivity (30, 128), as the human version is not required for infection of
murine cells.
Additional attachment/entry factors. The C-type lectins L-SIGN and D-SIGN bind E2
protein with high affinity. As such, it has been postulated that these receptors are involved in
initial attachment to the sinusoidal endothelial cells prior to transfer to hepatocytes, although
direct evidence to support this hypothesis does not exist (reviewed in (167)). Two reports also
demonstrate that the tight junction proteins claudin-6 and claudin-9 act as entry co-factors(99,
170), although these results were more significant with HCVpp compared to HCVcc(99).
Furthermore, a species-specific requirement for these receptors has not been demonstrated (30,
128)

The role of apolipoproteins in HCV attachment and entry
Apolipoproteins are small serum proteins that are associated with lipoproteins, including
chylomicrons, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density
lipoprotein (VLDL). Lipoproteins consist of a lipid core surrounded by cholesterol, apolipoproteins,
and phospholipids, and are important for transporting triglycerides to host cells and returning
excess cholesterol to the liver for excretion (132). Recent studies have suggested that
lipoproteins, as well as their associated apolipoproteins, may contribute to HCV virus attachment
and entry.
HCV particles generated from serum, when purified on a sucrose density gradient, exhibit
heterogeneous density and are most infectious if taken from the lower density fraction (71). As
the low-density fractions often contain serum lipoproteins, it was hypothesized that HCV might
interact with these components in such a way that augmented infectivity (7, 58). Recent studies
have confirmed that infectious HCV interacts directly with apolipoprotein C1 (ApoC1) and
apolipoprotein E (ApoE)(102, 112), and that human serum, HDL and ApoC1 enhance HCVpp
infection in an SR-B1 dependent fashion (12, 34, 36, 101, 156).
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HCV attachment and entry: a summary
HCV infection likely requires multiple host attachment factors and receptors acting in
concert to allow for internalization of the virus, such as occurs with Coxsackie B virus infection
(97). One model of HCV entry involves attachment via heparan sulfate, followed by interactions
with CD81, SR-B1, CLDN-1 and OCLN (reviewed in (167)). Indeed, experimental studies have
demonstrated that CD81, SR-B1 and CLDN-1 act cooperatively at early post-attachment steps
(77). OCLN likely acts at a post-attachment step as well, although its exact function remains
poorly understood (reviewed in (167)).

This complex model series of interactions may be

necessary to expose the CD81 binding site on E2, which is thought to be obscured by N-linked
glycans (62) and the HVR1 (5), in a manner similar to exposure of the CCR5 site of HIV after
engagement of the CD4 receptor (78, 135). Which, if any, of these receptors mediates viral
internalization remains unknown. Although further study is needed, recent data suggests that
tyrosine kinases, including EGFR, may initiate signaling events required for viral endocytosis (93).
Similar to flaviviruses (86), HCV is thought to undergo clathrin-mediated endocytosis (99)
into an endosomal compartment whereby low pH triggers envelope rearrangements required for
fusion and release of viral contents into the cytoplasm (11, 17, 25, 64, 79, 80, 153). In contrast to
flaviviruses(147), HCV is unable to undergo “fusion from without,” indicating both a high degree of
virus stability and that steps in the entry pathway are important for priming the endosomal fusion
event (100, 153). Viral fusion is classified structurally into two groups: i) type I fusion requires
proteolytic cleavage and rearrangement of a stalk-like protein trimer to expose the fusion peptide,
as is seen for the hemagglutanin protein of influenza; ii) type II fusion involves a pH-dependent
rearrangement of E protein dimers to form a trimer that exposes the fusion loop, as is seen in
flaviviruses and alphaviruses (61). HCV is predicted to utilize type II fusion based on its genome
arrangement and relationship to flaviviruses (40, 76), although experimental support for this
hypothesis is lacking.
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E2 glycoprotein
E2 is a type I membrane glycoprotein (109) that spans amino acids 384-746 of the viral
polyprotein(37) and is predicted to be exposed on the surface of the HCV virion (166). Full length
E2 protein contains 18 cysteines, which form nine intramolecular disulfide bonds (76), 11
potential N-linked glycosylation sites (51), and three hypervariable regions (HVR1, HVR2, and the
intergenotypic variable region (igVR)) (98, 160). E2 also contains both the CD81 binding domain
(127), the SR-B1 binding domain (139), and interacts with heparin (9).

While prior studies

suggested that E1 and E2 formed a non-covalent heterodimer (29, 38, 41, 110, 111, 162), these
studies were performed largely with intracellular E1 and E2; a recent study of HCVcc suggests
that E1 and E2 are covalently linked on the mature virion (154).
The HVR1 spans the first 27 amino acids (384-411) of the E2 protein (118, 160) and is
thought to facilitate viral immune escape from the host humoral response (161), mediate SR-B1binding (139), and shield the CD81 binding region(5). Antibodies directed to the HVR1 can limit
infection (44, 55, 137, 144, 171), however immune pressure generated by anti-HVR1 antibodies
also drives mutation in this region, leading to the selection of viral escape mutants (32, 44, 144,
161). Despite the increased propensity for mutation, the conservation of highly basic residues
within the HVR1 is critical for viral infectivity, suggesting that HVR1 interacts with anionic
molecules during viral attachment and entry(119).
The CD81 binding domain on E2 is comprised of several discontinuous segments
between amino acids 396-618, although the exact amino acids contacts remain unclear, with
conflicting data in the literature (37, 47, 113, 136, 162). Direct mutational analysis of E1-E2
suggests that the highly conserved residues W420, Y527, W529, G530 and T535 are minimally
required for CD81 binding (116), although others may exist. Indeed, some have predicted that
the HVR1(113, 136) as well as a short motif at G436 (G436WLAGFLY) (37) participate in CD81virus binding. The CD81 binding region is well protected on the surface of the virion, as it is
shielded by N-linked glycosylations(62).
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Despite intense efforts by academic and pharmaceutical laboratories, the crystal
structure of E2 remains unsolved. A recent predictive model based on experimental determination
of disulfide bonds and the structure of other type II fusion proteins suggests that E2 adopts a
three-domain structure similar to flaviviruses.

In this model, the putative domain I (DI) is

sandwiched between domain II (DII) and domain III (DIII) and is composed of two overlapping βsheets with the HVR1 extending from the amino-terminus as an unstructured segment. In this
structure, the CD81 binding residues are predicted to localize to the top β-sheet of DI and the
amino terminus of DIII. A group of highly conserved, non-polar residues (502-520) in DII were
suggested to form the HCV fusion loop (76), although experimental evidence is required to
corroborate this assertion.
Due to the importance of E2 in viral entry and attachment, it is not surprising that
antibodies against E2 protein confer protective immunity against HCV in vivo (23, 121, 137).
Many anti-E2 antibodies have been generated in vitro, including those with broad cross-reactivity
against multiple genotypes, such as AP33 (114). Table 1 lists the characteristics of MAbs
generated by other groups; the MAbs generated from my thesis are discussed in detail in Chapter
2.

Mechanisms of Antibody Neutralization
The importance of antibodies in controlling viral infection (reviewed in (117)), and
flavivirus infection in particular (reviewed in (124)), are well documented. Antibodies protect
against infection by direct binding and inhibition of viral infection (neutralization) as well as by
various effector functions, including opsonization, complement-mediated virolysis, and antibody
dependent cellular cytotoxicity (reviewed in(20, 117)). The following sections will focus on the
direct inhibition of viral infectivity by antibody binding and the stoichiometric requirements needed
to achieve this inhibition.
Pre- and Post-attachment neutralization. Antibodies can neutralize infection prior to viral
attachment to the host target cell (pre-attachment) or after viral attachment (post-attachment)
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(reviewed in (75)). Pre-attachment inhibition is posited to be due to coating of the virus such that
receptor interactions are inhibited either directly or by steric hindrance (20, 75, 117). Postattachment inhibition can occur at any number of steps in the viral life cycle after attachment,
including: i) blockade of binding to additional receptors after viral attachment, as demonstrated by
post-attachment inhibition of HCV infection by anti-CD81 and anti-SR-B1 MAbs (15, 56) as well
as MAbs that inhibit E2 binding to those receptors (138), ii) prevention of endocytosis, as has
been observed for MAbs V5 and E70 against human papilloma virus (28), iii) inhibition of viral
fusion, as has been described for MAb E16 antibody against West Nile Virus (WNV) (107, 151).
In some cases, antibodies may block both pre- and post-attachment steps. For example,
WNVE16 inhibits fusion at low concentrations yet can block attachment at high concentrations
(107, 151).
Stoichiometric requirements for neutralization. The “occupancy” or “coating” model of
neutralization states that a critical number of viral epitopes must be bound for neutralization to
occur (reviewed in (75, 117)). The ability of an antibody to achieve the minimum occupancy
requirement is governed by antibody affinity and the availability of the antibody epitope on the
surface of the virion. Antibody affinity is the strength with which an antibody binds its epitope and
can be expressed as KD=[V][MAb]/[VMAb], where KD is the dissociation constant, [V] is the
concentration of virus, [MAb] is the concentration of free MAb, and [VMAb] represents the
concentration of MAb bound to virus (75). In physical terms, the affinity determines the number of
epitopes bound at a given concentration of antibody (33), with the KD representing the
concentration of MAb needed to bind half of the available epitopes (75). The availability of
epitopes is governed by the virus structure; potential epitopes can be obscured beneath the
surface of the virion (84), by steric hindrance due to packing of molecular units on the viral
surface(125), or by N-linked glycosylation of envelope proteins (62). Additionally, cryptic epitopes
can be exposed by conformational changes in the virus, for example, the exposure of the CCR5
binding site of HIV after engagement of the CD4 receptor (78, 135). Thus, some epitopes may not
be sufficiently available for antibody to engage the virus above the minimum threshold required
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for neutralization (31). Recent evidence, however, does suggest that hidden epitopes may be
transiently exposed due to dynamic changes or “breathing” of the virus particle (31, 83, 84, 92).

Humoral response to HCV infection
The role of humoral immunity in HCV infection and the mechanism that is most important
for viral neutralization in vivo remain largely unknown. During acute infection, the appearance of
HCV specific antibodies is markedly delayed as compared to other viruses, with seroconversion
occurring roughly 6 to 8 weeks after infection (18, 106), although a recent study of intravenous
drug users (IDUs) during acute infection suggests that the early humoral response may not be
detected due to strain specificity of the initial antibodies produced (32). Detectable antibodies
against E1 and E2 glycoproteins usually appear later in infection, sometimes months after
seroconversion, and correspond with an increase in neutralizing antibody titers.

Neutralizing

titers increase over time (91, 106), and during chronic infection, some patients produce broadly
neutralizing antibodies against heterologous strains of virus(91, 101), although the presence of
these antibodies does not directly correlate with viral clearance, possibly due to viral escape from
the host response(32, 43, 157).
The importance of anti-E2 antibodies in controlling HCV infection has been suggested by
vaccination studies in which chimpanzees immunized with recombinant E1-E2 protein developed
protective humoral immunity (23, 137). Additionally, a study of patients accidentally infected with
HCV indicated that the development of an early neutralizing response correlated with an
increased probability of clearing infection (121). Anti-HCV antibodies also may function as
passive protection, and thus, in theory, could be used as post-exposure prophylaxis. Polyclonal
immune sera protects chimpanzees from infection either when pre-incubated with virus, (44, 165),
or when administered concomitantly with virus (165). A greater understanding of the mechanism
and function of anti-E2 antibodies in controlling HCV infection may guide the production of future
therapies and vaccines against HCV.
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Conclusions and Rationale
HCV infects ~170 million people worldwide and is a significant cause of morbidity and
mortality (18). Due to a lack of a tractable small animal model and, until recently, a cell culture
adapted virus, little remains known about the protective humoral immune response against HCV
infection. Neutralizing antibodies against the HCV E2 protein are found in infected patients (91,
101, 106), although the mechanisms by which these antibodies act and the epitopes to which
they bind remains poorly understood. The objective of this thesis is to study the molecular
mechanism of antibody mediated neutralization of HCV by the generation and characterization of
monoclonal antibodies (MAbs) against the E2 protein, with the hope that structural and molecular
understanding of neutralization will inform strategies for the development of novel therapeutics
and vaccines to treat and prevent HCV infection.
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Figure Legends
Table 1.1: Summary of MAbs previously generated against HCV E2
Summary of neutralizing and non-neutralizing MAbs previously generated against HCV
E2. The isotype, species in which the MAb was generated, capacity to inhibit binding to CD81,
and ability to neutralize are included, where applicable. N/D: Not done in the studies cited.
HuMAb mice: humanized antibody produced in genetically engineered mice.

17

Table 1.1: Summary of MAbs previously generated against HCV E2
Antibody Epitope
Isotype
Inhibits CD81 Species
binding?
AP33
L413, I414, N415,
N/D
Yes
mouse
T416, G418, W420,
H421
11/20c
E2 436-447
IgG2a
Yes
rat
6/16
HVR1
IgG1
No
rat
6/82a
HVR1
IgG1
No
rat
7/59
HVR1 .
IgM
No
rat
9/27
HVR1
IgG1
No
rat

Neutralization

References
(49, 113, 114,
118, 149)

rat
rat
rat
rat
rat
rat
rat
rat
rat

IgG2b

Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Conflicting
results
No

Yes; HCVcc;
HCVpp of all
genotypes
Yes; HCVpp
No
No
No
Yes; HCVpp;
Neutralization not
attenuated by HDL
No
No
Yes; HCVpp
Yes; HCVpp
Yes; HCVpp
No
No
No
No

rat

No

(64, 113)

N/D

Yes

rat

N/D

(47)

Conformational
epitope
Conformational
epitope
Conformational
epitope
464-471
464-475
644-651
464-475
640-653
648-651
644-651
N/D
N/D
N/D
N/D
N/D
W529A,
G530A,D535A,
G523A

N/D

No

mouse

N/D

(24, 47)

N/D

N/D

mouse

N/D

(29)

N/D

No

mouse

N/D

(47, 113, 118)

N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
IgG1

No
N/D
No
No
No
No
Yes
Yes
Yes
No
Yes
Yes

mouse
mouse
mouse
mouse
mouse
mouse
mouse
human
human
human
human
human
human

N/D
N/D
N/D
N/D
N/D
N/D
N/D
Yes; HCVpp
Yes; HCVpp
Yes; HCVpp
N/D
N/D
Yes; HCVpp of all
genotypes; HCVcc
(EC50=60ng/ml)

(113, 118)
(152)
(113)
(113)
(113)
(113)
(113)
(142)
(142)
(142)
(142)
(142)
(2, 69)

A8

W529A,
G530A,D535A,
G523A

IgG1

Yes

human

Yes; HCVpp of all
genotypes; HCVcc
(EC50=560ng/ml)

(2, 69)

L1

N/D

IgG1

N/D

human

Yes; HCVpp
No; HCVcc

(2, 69)

L3
A12
1:5
1:11
CBH-2

N/D
N/D
N/D
N/D
Conformational;
Binds domain “B”
Conformational; Binds
domain “A”
Conformational; Binds
domain “A”

IgG1
IgG1
FAb
FAb
IgG1

Yes,
Yes,
Yes
Yes
Yes

human
human
human
human
human

(2)
(2)
(2)
(2)
(57, 72, 115)

IgG1

No

human

N/D
N/D
N/D
N/D
Yes; HCVpp and
HCVcc
No

IgG1

No

human

No

(57, 72)

7/16b
9/75
3/11
1/39
2/69a
2/64a
6/1a
6/41a
6/53

436-446
524-531
N415, W420, H421
432-443
432-443
524-531
464-471
480-493
544-551

IgG2a
IgG2a
IgG2a
N/D
IgG2b
N/D
IgG1
IgG2a
IgG2a

9/86a

Conformational;
HVR1
644-655

H52
H/53
H2
H60
AP320
AP109
AP266
AP436
ALP98
ALP1
ALP11
HCV #1
HCV #4
HCV #7
HCV #12
HCV #13
1:7

CBH-4D
CBH-4B
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(47, 64, 113)
(47, 64)
(47, 64)
(47, 64)
(12, 47, 64,
156)
(47, 64)
(47, 64)
(47, 64, 149)
(47, 64)
(47, 64)
(64, 113)
(47, 64)
(47, 64)
(47, 64)

(57, 72)

CBH-4G

IgG1

No

human

No

(57, 72)

IgG1

No

human

N/D

(57, 72)

IgG1

Yes

human

Yes; HCVpp and
HCVcc

(57, 72, 115)

IgG1

Yes

human

(57, 72, 115)

IgG1

Yes

human

Yes; HCVpp and
HCVcc
No

IgG1

Yes

human

No

(57)[89]

IgG1

Yes

human

No

(57, 72)

IgG1
IgG1
IgG1
N/D

N/D
N/D
N/D
N/D

mouse
mouse
mouse
mouse

N/D
N/D
N/D
N/D

(41)
(41)
(41)
(122)

IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG3

N/D
N/D
N/D
N/D
N/D
N/D
Yes
No
N/D
Yes
N/D

IgG1

N/D

AR2A

N540A

IgG1

No

human
human
human
human
human
human
human
human
mouse
mouse
HuMAb
mice
HuMAb
mice
Human

AR3A

S424, G523, P525,
G530, D535, N540
S424, G530, D535

IgG1

Yes

Human

IgG1

Yes

Human

S424, P525, G530,
D535, N540
S424, G530

IgG1

Yes

Human

IgG1

Yes

Human

T416, N417, Y485,
V533, N540, W549
N540, P544, P545,
G547, W549
W529, G530, D535

IgG1

Yes

Human

N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
N/D
Yes; HCVpp from
multiple genotypes
Yes; HCVpp from
multiple genotypes
Yes; HCVpp and
HCVcc
Yes; HCVpp and
HCVcc
Yes; HCVpp and
HCVcc
Yes; HCVpp and
HCVcc
Yes; HCVpp and
HCVcc
No

(27)
(27)
(27)
(27)
(27)
(27)
(55)
(55)
(137)
(137)
(19)

95-2

Conformational; Binds
domain “A”
N/D; recognizes a
linear epitope
G523, P525, G530,
D535, N540;
conformational
N540, W549;
conformational
Conformational; Binds
domain “B”
Conformational; Binds
domain “B”
Conformational; Binds
domain “B”
E2 418-431
N/D
N/D
297-306 (E1),
480-494 (E2), and
608-622 (E2),
Conformational
Conformational
conformational
conformational
conformational
conformational
conformational
conformational
N/D
HVR1
L413, N415, G418,
W420,
L413, N415, W420.

IgG1

No

Human

No

(81)

FAb

N/D

Human

(96)

T416, W420, W529,
G530, D535

FAb

N/D

Human

Yes; HCVpp and
HCVcc
Yes; HCVpp and
HCVcc

CBH-17
CBH-5
CBH-7
CBH-8C
CBH-8E
CBH-11
H
All
I19
D32.10
4D2
7B7
1H3
2H8
3F12
2F7
503
108
291
12AG7
HCV1

AR3B
AR3C
AR3D
AR1A
AR1B
e20
e137

19

(57, 72)

(19)
(81)
(81)
(81)
(81)
(81)
(81)

(120)
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ABSTRACT
The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into
target hepatocytes and elicits neutralizing antibodies in infected patients. To characterize the
structural and functional basis of HCV neutralization, we generated a novel panel of 78
monoclonal antibodies (MAbs) against E2 proteins from genotypes 1a and 2a HCV strains. Using
high-throughput focus-forming reduction or luciferase-based neutralization assays with chimeric
infectious HCV containing structural proteins from both genotypes, we defined eight MAbs that
significantly inhibited infection of the homologous HCV strain in cell culture. Two of these bound
E2 proteins from strains representative of HCV genotypes 1-6, and one of these MAbs, H77.39,
neutralized infection of strains from five of these genotypes. The three most potent neutralizing
MAbs in our panel, H77.16, H77.39 and J6.36, inhibited infection at an early post-attachment
step. Receptor binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein
to both CD81 and SR-B1, J6.36 blocked attachment to SR-B1 and modestly reduced binding to
CD81, and H77.16 blocked attachment to SR-B1 only. Using yeast surface display, we localized
epitopes for the neutralizing MAbs on the E2 protein. Two of the strongly inhibitory MAbs, H77.16
and J6.36, showed markedly reduced binding when amino acids within hypervariable region 1
(HVR1) and at sites ~100 to 200 residues away were changed, suggesting binding to a
discontinuous epitope. Collectively, these studies help to define the structural and functional
complexity of antibodies against HCV E2 protein with neutralizing potential.
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INTRODUCTION
Hepatitis C virus (HCV) is a blood-borne, hepatotropic virus that infects ~170 million
people worldwide. Approximately 70% of infected individuals progress to chronic liver disease,
which carries an increased risk of cirrhosis and hepatocellular carcinoma (7). In general,
treatment of chronic HCV is complicated by resistance due to extensive genetic diversity. HCV
has been classified into seven major genotypes, which differ by ~30% at the nucleotide level (4),
and this positive-sense, single-stranded RNA virus has a capacity for rapid evolution of variant
viruses during persistent infection. The current treatment, pegylated IFN-a2a and ribavirin, has
variable side effects and response rates depending on the virus and host genotype (16). No
vaccine is currently available, and pre-clinical development has been hampered by a lack of
understanding of which conserved epitopes on the HCV structural proteins should be targeted.
HCV contains a ~9.6kb RNA genome that is translated as a single polyprotein and then
cleaved by viral and host proteases into structural proteins (core, E1, E2), p7, and nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (39). Viral attachment and entry is
mediated by the envelope glycoproteins, E1 and E2. Four attachment or entry receptors that are
required for infection of hepatocytes have been identified including CD81 (53), scavengerreceptor B1 (SR-B1) (56), and the tight junction proteins claudin-1 (CLDN1) (14), and occludin
(OCLN) (54). The importance of E2 binding to the large extracellular loop of CD81 has been
established in vitro (13, 18, 28, 50, 53), and interactions between E2 hypervariable region 1
(HVR1) and SR-B1 have been reported (3, 5, 56). The structural basis of binding of E2 to its
cognate cell attachment factors, however, is poorly understood, in part because high-resolution
structures of the HCV glycoproteins or intact virion have not been solved.
The role of the humoral immune response in controlling HCV infection in patients remains
controversial, as patients with persistent infection develop high-titer antibodies that do not appear
to clear infection (reviewed in (7)). Nonetheless, there are emerging data that classes of
monoclonal and polyclonal antibodies against HCV have protective activity. Binding to CD81 by
soluble forms of E2 (sE2, truncated proximal to the transmembrane domain) is inhibited by
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antibodies that also neutralize infection of pseudotyped HCV particles (HCVpp) derived from the
structural proteins of multiple genotypes (1, 45). Perhaps more convincing, experiments in
chimpanzees and chimeric mice have shown that passive transfer of anti-E2 antibodies protects
against infection (15, 37, 64), and immunization with E1-E2 virus-like particles and E2
glycoprotein in chimpanzees induces protective antibodies (10, 29, 37). Moreover, in a
comprehensive study of neutralizing MAbs derived from infected patients, MAbs that bound
regions comprised of amino acid residues 396–424, 436–447 and 523–540 on E2 neutralized
HCVpp derived from multiple genotypes (37). Thus, anti-E2 antibodies apparently can restrict
HCV infection, although the exact steps (attachment, entry, or fusion) in the viral entry process
that are inhibited and the corresponding E2 binding epitopes have not been elucidated.
To gain more insight into the molecular and structural basis of anti-E2 antibody
neutralization of HCV infection, we generated a panel of 78 mouse monoclonal antibodies (MAbs)
against soluble, recombinant E2 proteins derived from genotypes 1a (H77 strain) and 2a (J6
strain) HCV strains. These MAbs were analyzed for inhibitory activity against infectious HCV in
cell culture and assessed for mechanism of action with respect to inhibition of ligand binding on
the cell surface. By combining this functional analysis with a high-throughput yeast surface
display mapping strategy, we identified neutralizing MAbs that bound to distinct regions of E2,
including MAbs that recognized determinants with discontinuous epitopes with primary
sequences greater than 100 amino acids apart. These experiments suggest that neutralizing
MAbs blocking distinct stages of the HCV cell entry process recognize discontinuous epitopes on
the E2 protein.
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MATERIALS AND METHODS
Cells and viruses. Huh-7.5 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Equitech), non-essential amino acids
(Gibco), and antibiotics (penicillin G and streptomycin) at 37°C in a 5% CO2 incubator. SF9 cells
o

were cultured in Grace’s Insect cell medium (Gibco) supplemented with 10% FBS at 28 C. HI-5
o

cells were cultured in Ex-cell media (Gibco) at 27 C. CHO cells were grown in Ham’s F12
medium (Gibco) supplemented with 10% FBS (HyClone) at 37°C.
The genotype 2 J6/JFH1/JC1 HCV chimera that expresses luciferase (58) was a
generous gift from Apath Inc. The HJ3-5 H77/JFH1 chimera, which expresses the core-NS2
segment of the genotype 1a polyprotein within a genotype 2a background has been described
(40, 67). The genotype 1a H77C/JFH1(57), genotype 2a J6/JFH1 (38), genotype 3a S52/JFH1
(23), genotype 4a ED43/JFH1 (57), genotype 5a SA13/JFH1 (32), and genotype 6a HK6a/JFH1
(24) infectious HCV recombinants used in cross-neutralization studies also have been described.
Cell culture compensatory and adaptive mutations for the HJ3-5, S52/JFH1, ED43/JFH1,
SA13/JFH1 and HK6a/JFH1 chimeras have been described (24, 40, 67).
To generate virus stocks from infectious cDNA clones, plasmids were linearized and RNA
transcription was performed using the T7 DNA-dependent RNA polymerase (MEGAscript Kit,
Ambion). Infectious HCV RNA (2 mg) was electroporated as described (38), and virus was
harvested at 48, 72, and 96 hours, sterile filtered (0.2 mm filter, Corning Inc), and buffered with
10mM HEPES pH 7.2 (Mediatech, Inc.). Virus was stored at 4°C for short-term usage or aliquots
were prepared and stored at -80°C. Virus titration on Huh-7.5 cells was performed by TCID50
assay as previously described (38).
Generation of CHO cells stably expressing HCV cell entry factors. Human SR-BI and
CD81 genes were expressed in CHO cells via lentivirus transduction in the context of pTRIP, a
self-inactivating lentiviral provirus that expresses no HIV proteins but instead employs an internal
cytomegalovirus (CMV) promoter to express cloned genes. An intermediate plasmid, called TRIPGFP-linker, was generated as a backbone into which SR-BI and CD81 were cloned (all entry
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factor templates were kindly provided by C. Rice, Rockefeller University, NY). TRIP-GFP-linker
was generated by amplifying the GFP sequence with the forward oligonucleotide 5’-CGC AAA
TGG GCG GTA GGC GTG and reverse oligonucleotide 5’-CTC GAG CTA GTC GAC TTC GAA
ACT AGT GCT AGC CCG CGG CTT GTA CAG CTC GTC CAT GCC. This PCR product was
digested with restriction enzymes BamHI and XhoI and ligated into the TRIP-GFP plasmid
digested with the same enzymes. The human SR-BI sequence was amplified with forward
oligonucleotide 5’-CCG CGG ATG GGC TGC TCC GCC AAA GCG and reverse oligonucleotide
5’-GCT AGC CAG TTT TGC TTC CTG CAG CAC from the previously described TRIP-hu-SR-BI
plasmid (54) to generate TRIP-GFP-hu-SR-BI-linker. This PCR product was digested with SacII
and NheI and ligated into similarly digested TRIP-GFP-linker. The human CD81 sequence was
amplified from an expression construct, TRIP-GFP-hu-CD81(56), with forward oligonucleotide 5’GCT AGC ATG GGA GTG GAG GGC TGC ACC and reverse oligonucleotide 5’-ACT AGT GTA
CAC GGA GCT GTT CCG GAT. This PCR product was digested with NheI and SpeI and ligated
into similarly digested TRIP-GFP-linker to generate TRIP-GFP-hu-CD81-linker.
Pseudoparticle production was performed as previously described (54) by co-transfection
of three plasmids encoding a TRIP provirus containing a transgene, HIV Gag-Pol, and the VSV-G
6

glycoprotein. 293-T cells were seeded at 1.8 x 10 cells/well into a poly-L-lysine (Sigma)-coated
six-well plate. Transfection was performed the next day using a total of 1.5 mg of DNA plasmid,
with 6 ml of TransIT-LT1 transfection reagent (Mirus). Supernatants were collected 24, 48, and 72
h post-transfection, filtered (0.45-mm pore size), and mixed with 100 ml of 1 M HEPES buffer. All
transductions were performed in the presence of 4 mg/ml Polybrene (Sigma). Receptor
expression was verified by flow cytometry using the following protocol: cells were lifted using PBS
supplemented with 4 mM EDTA and 10% FBS, washed, and pelleted in a V-bottom plate. Cells
5

(10 ) were incubated with either 20 mg/ml of mouse anti-hu-CD81 (BD Biosciences) or rabbit antihu-SR-B1 (Ab-Cam) for 30 minutes on ice, washed, and then incubated with goat anti-mouse IgG
or goat anti-rabbit IgG secondary antibody conjugated to Alexa Fluor 647 (Molecular Probes).
Cells were washed twice and receptor expression was analyzed on a FACSArray flow cytometer
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(Becton-Dickinson) using FloJo software (Tree Star).
Cloning, expression, and purification of recombinant HCV E2. The E2 protein
ectodomain of strains H77 (aa 384-661) (35) or J6 (aa 385-661) was cloned into a baculovirus
expression vector (pFastBac derivative) from plasmids containing the structural proteins of H77
(gift of M. Gale, Jr., University of Washington) or the infectious J6/JFH1/JC1 (58) viral genome
(gift of Apath, Inc). The baculovirus expression vector adds a honeybee melittin signal peptide at
the NH2 terminus and a thrombin-cleavable His6 tag and stop codon at the COOH-terminus.
Recombinant baculoviruses expressing HCV E2 ectodomains were generated as described
previously (31), amplified in SF9 cells, and used for large scale infection of Hi-5 cells under
serum-free conditions. Supernatant was concentrated and buffer exchanged into binding buffer
(300 mM sodium citrate, 150 mM sodium chloride, 50 mM sodium phosphate pH 8.0) using a
Centramate tangential flow concentrator. E2 was purified by sequential nickel-affinity and sizeexclusion chromatography and monodispersed fractions of monomeric protein were collected and
used for subsequent studies.
Generation, purification, and labeling of anti-HCV MAbs. MAbs were generated by
five independent splenocyte-myeloma fusions as described (43). Mice were immunized via an
intraperitoneal route with sE2 produced from either genotype 1a (H77) or 2a (J6) HCV strains
after complexing with RIBI Adjuvant System (Corixa Corp) or complete Freund’s adjuvant (Sigma
Chemical). Mice were boosted between two and five times with homologous HCV sE2 protein
complexed with either incomplete Freund’s adjuvant (Sigma), RIBI Adjuvant System (Corixa), or
Sigma Adjuvant system (Sigma), depending on commercial availability, until adequate titers
(>1:2500 by ELISA) were achieved. Mice with the highest serum titers were boosted
intravenously with purified sE2 (50 mg) three days prior to fusion of splenocytes with
P3X63Ag8.53 myeloma cells (12). Hybridomas producing anti-HCV E2 antibodies were identified
after binding to Saccharomyces cerevesiae yeast expressing sE2 on their surface by flow
cytometry, subcloned by limiting dilution, and isotyped by ELISA. For large-scale production,
MAbs were generated from ascites or adapted to growth in Hybridoma Serum Free Media (Gibco)
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and purified using protein A or G affinity chromatography (Pierce). In some experiments, MAbs
were labeled with Alexa Fluor 647 (Molecular Probes) or NHS-FITC (Pierce) MAb labeling kits
according to the manufacturer’s instructions.
Virus neutralization assays. Neutralization of HCV infection by viruses containing
genotype 1a structural proteins (H77/JFH1) was assessed by a focus forming unit (FFU) assay.
Serial dilutions of HCV-specific MAb, control MAb (WNV E16 (43)), anti-human CD81 (clone
JS81, BD Biosciences), or anti-human SR-B1 (clone 396, Ab-Cam) were pre-incubated with 2.4 x
2

10 FFU of virus for one hour at 37°C. Virus-MAb mixtures were added to Huh-7.5 cells (1.2 x 10

4

cells per well) in a 48-well tissue culture plate pre-coated with poly-L lysine (Sigma). After 72
o

hours, cells were fixed with methanol (0 C), and incubated sequentially with a mouse anti-NS5A
(APA-1, 40 ng/ml) (38) (a generous gift of Apath, Inc.) and secondary goat anti-mouse HRP
diluted 1:3000 (Sigma). FFU were visualized using the True Blue Peroxidase Reagent (KPL) and
quantitated using an S5 Biospot Macroanalyzer (Cellular Technologies Ltd). EC50 values were
determined using non-linear regression analysis (Graph Pad Prism 4).
Neutralization of the genotype 2a (J6/JFH1/JC1) HCV was assessed by luciferase assay.
Serial dilutions of HCV-specific or control MAbs were pre-incubated with the J6/JFH1/JC1 virus
2

that expresses luciferase (10 FFU) for one hour at 37°C and then added to Huh-7.5 cells (10

4

cells per well) in a 96-well black flat bottom polystyrene-treated microplate (Corning). After 48
hours, cells were lysed and luciferase was detected using the Renilla Luciferase Assay System
(Promega) according to the manufacturer’s instructions. EC50 values were determined using
non-linear regression analysis (Graph Pad Prism 4).
Neutralization of chimeric viruses with genotype 1a-6a specific core-NS2 sequences was
assessed by FFU assay as previously described (55). Briefly, 50 to 400 TCID50 of HCV were
incubated 1 hour at 37°C with MAb H77.39 or an isotype control and then incubated with cells for
3 hours. After 48 hours, cells were immunostained for NS5A as previously described (23). FFU
counting was automated using ImmunoSpot Series 5 UV Analyzer (22). Percent neutralization
was calculated by relating FFU counts to mean of six-replicates incubated in the absence of
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antibody (virus only). Neutralization data were analyzed as variable slope dose-response curves
using GraphPad Prism 4.0 and EC50 values were interpolated by the software.
Pre-and post virus attachment assays. To assess the ability of MAbs to inhibit
H77/JFH1 virus at pre- and post-attachment steps, FFU assays were modified as follows. For the
2

post-attachment assay, pre-chilled cells were incubated with 4.8 x 10 FFU of virus for one hour
at 4°C. Cells were washed thrice with cold DMEM to remove unbound virus and MAbs (diluted to
50 mg/ml in media and pre-warmed at 37°C) were added and the cells shifted to 37°C. After one
hour, a 1:1 MEM-methylcellulose overlay with 4% FBS was added to prevent viral spread. For the
2

pre-attachment assay, 4.8 x 10 FFU of virus were pre-incubated with 50 mg/ml of media for one
hour at 37°C and then added to pre-seeded Huh-7.5 cells.
To assess the ability of MAbs to inhibit J6/JFH1/JC1 at pre- and post-attachment steps,
the luciferase assay was modified in the following manner. 48-well tissue culture plates were pre4

coated with poly-L lysine (Sigma) and seeded with 1.2 x 10 cells per well.

For the post-

2

attachment assay, 4.8 x 10 FFU of virus was added to pre-chilled cells and “spinoculated” for 45
minutes at 400 x g at 4°C, followed by a 15 minute incubation at 4°C. Cells were washed and
pre-warmed MAbs and methylcellulose were added as described above. For the pre-attachment
2

assay, 4.8 x 10 FFU of virus were pre-incubated with 50 mg/ml of MAb for one hour at 37°C and
then added to pre-seeded Huh-7.5 cells. Cells from both the pre-and post-attachment assay were
lysed after 48 hours and transferred to a 96-well black-bottom plate and luciferase was detected
using the Renilla Luciferase Assay System (Promega) according to the manufacturer’s
instructions.
Cross-reactivity and mapping analysis of MAbs using yeast surface display. To
assess MAb cross-reactivity with other HCV genotypes, the ectodomain of the E2 genes from
genotype 1a (H77, amino acids 384 to 660), genotype 2a (J6, amino acids 385 to 664), genotype
3a (UKN 3A13.6, amino acids 385 to 667), genotype 4a (UKN 4.21.16, amino acids 392 to 663),
genotype 5a (SA13 NIH, amino acids 384 to 663) and genotype 6a (UKN 6, amino acids 385 to
668) was amplified by PCR with BamH1 and XhoI sites for cloning added at the 5’ and 3’ ends,
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respectively. The PCR products were cloned as downstream fusion proteins to the Aga2 gene in
the pYD1 vector (Invitrogen) for expression on the surface of yeast. To determine the relative
binding regions on E2 of specific MAbs, COOH-terminal truncation constructs, based on previous
studies (41) were generated for genotypes 1a and 2a corresponding to regions I (amino acids
384 to 520 in genotype 1a and 384 to 518 in genotype 2a) or I and II (amino acids 384 to 605 in
genotype 1a and 384 to 603 in genotype 2a) and displayed on the surface of yeast.
Expression constructs were transformed into Saccharomyces cerevisiae strain EBY100
(17) using the S.c. EasyComp transformation Kit (Invitrogen). Individual yeast colonies were
grown to logarithmic phase at 30°C in tryptophan-free yeast selection media containing 2%
glucose. Protein expression was induced by cultivating yeast for an additional 48 to 72 hrs in
tryptophan-free media supplemented with 2% galactose at 20°C. Yeast cells were washed with
PBS containing 1 mg/ml BSA (PBS/BSA) and incubated with 40 ml of MAb (neat supernatant or
20 mg/ml purified diluted in PBS) for 30 minutes on ice. Yeast were washed in PBS/BSA,
incubated with goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 647 (Molecular
Probes) for 30 minutes on ice, washed, and analyzed on a FACSArray flow cytometer (BectonDickinson) using FloJo software (Tree Star).
Random mutant libraries of E2 were generated from genotype 1a (H77 strain) and
genotype 2a (J6 strain) genes by error-prone PCR using a GeneMorph II random mutagenesis kit
(Stratagene). Libraries were ligated into the pYD1 vector and transformed into XL2-Blue
5

5

ultracompetent cells (Stratagene) with ~5.7 x 10 and 5.5 x 10 transformants for genotypes 1a
and 2a, respectively. Screening of the libraries for loss of binding variants was performed as
described (43, 59). In brief, yeast expressing E2 variants that lost specific binding to individual
MAbs were sorted using two-color flow cytometry. To eliminate mutations that abolished surface
expression of E2, yeast were stained sequentially with the Alexa Fluor 647-conjugated individual
MAb, followed by a FITC-conjugated oligoclonal pool of the cross-reactive MAbs (J6.1, J6.2,
J6.16, J6.39, J6.51, and J6.101 for the genotype 1a library and J6.2, J6.14, J6.15, J6.39, J6.51,
and J6.99 for the genotype 2a library) on ice for 30 minutes. Yeast that stained positively for the
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oligoclonal pool but negatively for the MAb of interest were collected, cultivated, and iteratively
sorted. In some cases, sorting was performed using MACS LS magnetic columns (Miltenyi
7

Biotech). In brief, ~10 yeast cells were pelleted and resuspended in MACS buffer (PBS + 0.5%
BSA+ 2mM EDTA) containing a 1:50 dilution of a FITC-labeled MAb of interest for 30 minutes,
washed, and then incubated with 10 ml of anti-FITC microbeads (Miltenyi Biotech) on ice for 15
minutes. Yeast were washed and passed over a MACS LS column and the flow-through
collected. After four to five rounds, yeast were plated and individual colonies were tested for
binding to individual MAbs by flow cytometery. For clones that lost binding to the desired MAb of
interest, the plasmid was recovered using a Zymoprep yeast minipreop kit (Zymo Research),
transformed into XL1-Blue competent E. coli, purified using a QIAprep spin miniprep kit (Qiagen)
and sequenced. In cases where more than one mutation was detected, site-specific mutagenesis
using the Quick Change II Mutagenesis kit (Stratagene) was used to generate individual
mutations within the E2 protein to define the mutant of interest.
Inhibition of CD81 and SR-B1 binding. To assess the ability of neutralizing MAbs to
inhibit binding of sE2 to CD81 and SR-B1, 50 mg/ml of purified MAb was pre-incubated with 20
o

mg/ml H77 E2 or J6 sE2 for 30 minutes at 37 C. CHO cells expressing HCV receptors were
detached with PBS supplemented with 4 mM EDTA and 10% FBS, and washed three times in
5

medium. Cells (10 ) were pelleted in a V-bottom plate, resuspended with MAb-protein mixture,
and incubated on ice for 30 minutes. Cells were washed and then incubated with a pool of Alexa
Flour 647 labeled anti-E2 MAbs (J6.1, J6.2, J6.39, J6.51, H77.30, and H77.34 for the detection of
H77 E2; and J6.2, J6.39, J6.51, J6.60, and J6.101 for the detection of J6 E2) for 20 minutes on
ice. Cells were washed twice and sE2 binding was analyzed on a FACSArray flow cytometer
(Becton-Dickinson) using FloJo software (Tree Star).
Statistical analysis. All data was analyzed using Graphpad Prism software (version 4.0).
For neutralization assays and receptor-binding assays, an unpaired t-test was used to determine
statistical significance.
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RESULTS
MAb generation. Previous studies have demonstrated that HCV-specific monoclonal
and polyclonal antibodies, particularly those that recognize the E2 protein, can control HCV
infection in vitro and in vivo (10, 15, 33, 37, 47, 62). However, only a few of these antibodies have
been characterized for their ability to inhibit at different stages of HCV infection or mapped to
epitopes at the amino acid level. To better define the structural basis of antibody neutralization of
HCV, we generated a new panel of anti-HCV MAbs by immunizing BALB/c mice with soluble,
recombinant E2 protein that was expressed in insect cells and derived from either genotype 1a
(H77 strain, amino acids 384-664) or genotype 2a (J6 strain, amino acids 385-664) viruses. After
five independent splenocyte-myeloma cell fusions, we subcloned 37 MAbs from genotype 1aimmunized mice and 41 MAbs from genotype 2a-immunized mice, all with reactivity against the
E2 structural glycoprotein of HCV (Table S1).
Neutralizing activity of anti-E2 MAbs. To study the inhibitory capacity of genotype 1a
MAbs in cell culture, we utilized an H77-JFH1 chimeric infectious virus that contains genotype 1a
core-NS2 sequence in the JFH1 background, with a compensatory Q221L mutation in NS3
(pHJ3-5) (40, 67). For high-throughput screening, we adapted a focus-forming unit (FFU) assay
with Huh-7.5 cells such that infectious foci were scored objectively on an ELISPOT reader and
the reduction in number of FFU was assessed after pre-incubation of virus with individual MAbs
(Fig 1A). We performed a single endpoint focus reduction neutralization test (FRNT) using neat
antibody supernatant (~10 mg/ml) and identified 9 MAbs that inhibited infection by 40% or greater
(Fig 1B). Candidate neutralizing MAbs identified above and other selected antibodies were
purified by immunoaffinity chromatography and tested for inhibitory activity with a more complete
dose-response curve (Fig 1C). We demonstrated that five of these MAbs (H77.16, H77.28,
H77.31, H77.39 and H77.56) had reproducible neutralizing activity and determined the
concentration of MAb at which 50% of foci were inhibited (EC50 value) (Fig 1C). Of these MAbs,
H77.16 and H77.39 showed the greatest inhibitory activity, with EC50 values of ~3.4 μg/ml and
~1.1 μg/ml, respectively.
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To evaluate the neutralizing activity of MAbs generated against E2 derived from the
genotype 2a HCV strain, we utilized a genotype 2a J6/JFH1/JC1 infectious chimera of HCV that
contains a Renilla-luciferase reporter gene inserted immediately upstream of NS2A cleavage site
(58). All 41 MAbs that bound the genotype 2a E2 protein were purified and assessed for inhibitory
activity over a broad range of concentrations to determine the concentration of antibody that
reduced luciferase expression by 50% (EC50 value) (data not shown). We identified two
antibodies, J6.36 and J6.103 that efficiently neutralized infection, (Fig 1D) with J6.36 having an
EC50 value below 2 mg/ml. Notably, no significant difference in inhibitory potency of a given
neutralizing MAb was observed when the luciferase and FRNT assays were directly compared
(data not shown).
Cross-reactivity of anti-E2 MAbs. HCV is comprised of six epidemiological important
genotypes with ~70% nucleotide identity (4). A better understanding of the specific epitopes that
are conserved and recognized by inhibitory antibodies may facilitate the design of future
vaccines. To begin to address this, we assessed how genotype variation affected MAb reactivity
using recombinant E2 proteins displayed on yeast (1a, H77; 2a, J6; 3a, UKN3a; 4a, UKN4a; 5a,
SA13; and 6a, UKN6) and neutralization capacity with chimeric HCV strains (1a, H77; 2a, J6; 3a,
S52; 4a, ED43; 5a, SA13; and 6a, HK6a) containing the non-structural proteins (NS3-NS5B) of
the genotype 2a JFH1 strain and structural proteins, p7, and NS2 from strains representative of
HCV genotypes 1-6.
(a) Binding to different HCV genotypes. The ectodomain of E2 from individual strains
corresponding to HCV genotypes 1-6 was expressed on the surface of yeast, incubated with
MAbs, and analyzed for binding by flow cytometry. Three of the eight neutralizing MAbs were
broadly cross-reactive and recognized all five (H77.16 and H77.39) or four of the five (H77.56)
heterologous genotypes (Fig 2 and Table 1). Three of the neutralizing MAbs (H77.31, J6.36, and
J6.103) bound to yeast expressing only the homologous E2.
(b) Cross-neutralizing potential of MAbs. As MAb binding capacity to recombinant viral
structural proteins does not always directly correlate with neutralizing potential (8), we evaluated

44

the inhibitory activity of several of the cross-reactive MAbs against HCV virus of other genotypes.
Initially, single endpoint focus reduction assays were performed with high concentrations (50
mg/ml) of purified MAbs generated against genotype 1a or genotype 2a that cross-reacted with
genotype 2a or genotype 1a E2, respectively (Fig 3A and 3B). Of the cross-reactive MAbs
generated against genotype 1a E2, only H77.39 neutralized the genotype 2a virus. Of the crossreactive MAbs generated against genotype 2a E2, only J6.27 inhibited genotype 1a HCV infection
(Fig 3B and 3C). This was surprising because J6.27 lacked neutralizing activity against the
genotype 2a strain against which it was generated (Fig 3C); this pattern of enhanced neutralizing
activity of cross-reactive antibodies against the heterologous virus also has been observed with
MAbs against distantly related flaviviruses (2, 44). H77.39 inhibited the genotype 2a virus with an
EC50 value of ~5 mg/ml (Fig 3D), which was comparable to that observed with the genotype 1a
virus (see Fig 1C). We subsequently tested whether H77.39 neutralized infection of a panel of
chimeric viruses that expressed structural proteins from the remaining heterologous HCV
genotypes. H77.39 dose-dependently inhibited HCV infection of genotypes 3a, 4a, and 5a but
showed reduced activity against a virus containing structural proteins of genotype 6a (Fig 3E).
Mechanism of MAb neutralization. Antibody neutralization may involve different stages
of viral infection including attachment, internalization, or fusion (51). To begin to understand how
our inhibitory MAbs blocked infection, we performed pre- and post-attachment neutralization
assays and binding studies to the CD81 and SR-B1 receptors.
(a) Pre- and post-attachment assays. To identify the stage of infection at which MAbs
neutralize infection, we adapted a pre- and post-attachment inhibition assay originally developed
for flaviviruses (42, 60, 66). Purified anti-E2 MAb was incubated with virus before or after
attachment at 4°C to Huh-7.5 cells, and infection was measured by a single endpoint focus
reduction assay. Of the nine neutralizing MAbs tested, three (H77.16, H77.39, and J6.36)
significantly reduced infection compared to the negative control MAb (WNV E16) when added
after viral absorption to a cell monolayer, suggesting blockade of a post-attachment step (Fig 4AD). Interestingly, both anti-CD81 and anti-SR-B1 MAbs also inhibited infection after viral
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adsorption, confirming previous results in Huh-7.5 cells which suggested that HCV binds to CD81
and SR-B1 after initial attachment (6, 25). Inhibition of infection at a post-attachment step by
H77.39 was confirmed by performing more complete dose-response curve analysis (Fig 4E).
(b) MAb inhibition of sE2 binding to receptors. Given that anti-CD81, anti-SR-B1, and
several anti-E2 MAbs all blocked after HCV attached to Huh-7.5 cells, it was difficult to discern
whether some antibodies blocked binding to individual HCV receptors. To address this, we
developed a binding assay for soluble E2 (sE2) to CHO cells that ectopically expressed human
CD81 or SR-B1. CHO cells were transduced with a lentiviral vector encoding CD81 or SR-B1
fused to GFP. Surface staining of intact cells with anti-CD81 and anti-SR-B1 MAbs confirmed
high-level receptor expression (Fig 5A), as did analysis of cells for GFP fluorescence (data not
shown). Binding of genotype 1a (Fig 5B) and genotype 2a (Fig 5C) sE2 to CD81 and SR-B1
expressing CHO cells (solid histograms), but not control CHO cells (outlined histograms) was
confirmed by flow cytometry. To determine whether sE2-CD81/SR-B1 receptor interactions could
be disrupted by anti-E2 MAbs, neutralizing or control (anti-WNV E16) MAbs were pre-incubated
with sE2, added to wells containing CHO cells expressing CD81 or SR-B1, and loss of binding
was assessed by flow cytometry (Fig 5D). The neutralizing MAb H77.39 significantly blocked
(>70%, P < 0.01) sE2 binding to both CD81 and SR-B1. In comparison, H77.31 also reduced
binding of sE2 to both receptors, although inhibition of SR-B1 binding was more modest (~40%, P
= 0.04) compared to that seen with CD81 (>80%, P = 0.003). Conversely, J6.36 efficiently
inhibited sE2-SR-B1 binding (>80%, P = 0.0002) yet only modestly (~50%, P < 0.05) diminished
sE2-CD81 binding. H77.16 and J6.103 blocked sE2 binding to only a single receptor, with both
efficiently reducing (>75%, P = 0.0005) binding to SR-B1 (Fig 5D). Three neutralizing MAbs,
H77.28, H77.56, and J6.27, did not inhibit significantly sE2 attachment to either CD81 or SR-B1,
suggesting that these may block an alternate attachment or entry step (Fig 5E).
Epitope localization of MAbs. To correlate the function of the anti-E2 MAbs with
structure of the HCV E2 protein, we localized their epitopes using a previously validated yeast
surface display mapping assay (43, 44, 61). Initially, COOH-terminal truncated versions of E2,
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based on those described previously (41), were displayed on the surface of yeast and MAbs were
tested for immunoreactivity by flow cytometry (Fig 6 and Table S1). Neutralizing MAbs showed
different requirements for binding. H77.16, H77.39, J6.36, and J6.103 bound to a region
bracketed by amino acids 384-520 of genotype 1a and 384-518 of genotype 2a E2 (designated
“region I”), whereas H77.28, H77.31, and J6.27 required amino acids 521-605 of genotype 1a or
519-603 of genotype 2a E2 (designated “region II”) for binding. In contrast, MAb H77.56 required
the full E2 ectodomain (1-664), suggesting that it interacts with amino acids 606-664 alone or
requires a conformation of E2 that this region stabilizes. MAbs that neutralized efficiently at a
post-attachment step, H77.16, H77.39 and J6.36, all bound to region I of E2.
To localize MAb epitopes more clearly, we used error-prone PCR mutagenesis and yeast
surface display to create a library of H77 and J6 E2 variants to define individual amino acid
binding residues of neutralizing and non-neutralizing MAbs. Yeast that lost expression of
individual MAb epitopes were sorted by flow cytometry and plasmids were recovered, sequenced,
and tested for reactivity against a select panel of MAbs (Fig 7 and Tables 2 and 3).
H77.39, the most potent and highly cross-neutralizing MAb, showed markedly reduced
binding when residues N415 and N417 of E2 were changed (Fig 7A and Table 2). Two
neutralizing MAbs (J6.36, and J6.103) showed significant loss of binding when a pair of mutations
was introduced. J6.36 and J6.103 lost binding with changes in HVR1 and a more distal region of
E2; mutation of residues G406, F403, or a combined mutation at residues G397 and R572
abrogated MAb binding. Single mutations of G397 and R572, however, did not affect binding (Fig
7B and Table 3). Similarly, H77.16 showed weakly reduced binding when a serine was
introduced at residue G406 (Fig 7A), but complete loss of binding when residue G530 was
altered in combination with G406S. However, complete loss of H77.16 binding also was observed
when residue G406 was mutated to an aspartic acid residue.
The neutralizing MAbs that were quantitatively weaker in our neutralization assays,
H77.31 and J6.27, showed decreased binding when residues in the putative CD81 binding region
(amino acids 523-535 (48)) were changed. H77.31 binding to E2 on yeast was lost when residues
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W529, G530, and D533 were mutated, whereas J6.27 binding was abolished when amino acids
A524 and W529 were altered. The remaining two weakly neutralizing MAbs (H77.28 and H77.56)
showed reduced binding with changes at residues R543 and C552, respectively (Fig 7A and
Tables 2 and 3).
Some non-neutralizing MAbs also were mapped. Several non-neutralizing MAbs (H77.27,
H77.36, J6.2, J6.6, J6.15, J6.39, and J6.85) shared residues that impacted binding of H77.31 or
J6.27 (Tables 2 and 3), and a few (J6.2, J6.6, J6.40, and J6.101) had total or partial loss of
binding to residue G406, which was identified as an important recognition residue for the
neutralizing MAbs H77.16, J6.36 and J6.103. In addition to G406, J6.2, J6.40 and J6.101
recognition was also affected by mutation of residue H621, thus defining another discontinuous
epitope, albeit one that is not apparently involved in neutralization (Fig 7 and Tables 2 and 3).
Additional residues that uniquely affected binding by non-neutralizing MAbs included G470
(H77.14 and H77.23), S440 (J6.60), Y443 (J6.60), and H621 (J6.30).
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DISCUSSION
In this study, we generated a novel panel of 78 MAbs against the E2 proteins of HCV
genotypes 1a and 2a, analyzed them functionally for inhibition of HCV infection, and localized
epitopes using yeast surface display of truncated and substituted forms of the E2 protein. We
defined MAbs that mapped to distinct regions of E2, neutralized infection at different stages, and
differentially affected CD81 and SR-B1 engagement. Our mapping data also suggests a tertiary
interaction between the HVR1 and the COOH-terminal membrane proximal regions of E2, which
provides new insight into the quaternary structural aspects of neutralization by functionally
relevant antibodies.
Prior mapping studies of anti-E2 MAbs have utilized peptide binding (9, 18), phage
display (65), alanine scanning mutagenesis of recombinant E1-E2 (33, 37, 49, 62) or E2, (34), or
generation of neutralization escape mutants (19) to localize antibody binding sites. In comparison,
we used a forward genetic mutational approach coupled with yeast surface display to identify
mutants in the context of the entire ectodomain of E2 protein in an unbiased manner. Three of our
eight neutralizing MAbs showed loss-of-binding phenotypes with paired amino acid mutations
greater than 100 amino acids apart in the linear sequence, suggesting that discontinuous regions
of E2 come together to create functionally important antibody epitopes. H77.16 showed a loss-ofbinding phenotype when mutations in the HVR1 (e.g., G406S) and the more COOH-terminal
residue (G530A) were paired, suggesting that H77.16 binds a conformational epitope. Although
complete loss of binding could be achieved with a single less conserved mutation (G406D), the
more conserved G406S change required a second mutation at a discontinuous site (G530) for
loss-of-binding. This finding, which suggests that the HVR1 interacts with more COOH-terminal
residues, is consistent with MAb competition studies with recombinant proteins that suggested
that amino acids 396-424, 436-447, and 523-540 comprise an antigenic region (designated
“antigenic region-3”) within E2 (37), and with sequencing results of MAb AP33 escape variants,
which identified non-contiguous amino acid residues (N415 and E655) as factors in the loss of
neutralization phenotype (19). Additionally, these data support the recently described model of
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HCV E2 based on the three domain structure of class II E proteins in Flaviviridae and
Togaviridae, which predicts that the HVR1 proximally apposes the proposed HCV Domain I (D1)
(36) (Fig 8B).
Two other neutralizing MAbs, H77.31 and J6.27, also recognized residues within the third
segment of antigenic region-3 (A524, W529, G530 and D533) but did not show a loss-of-binding
phenotype when amino acids within segment 1 (396-424) were changed. These two MAbs less
potently neutralized infection and were less cross-reactive. In comparison, human anti-HCV
MAbs (A8, 1:7, and CBH5) that share epitopes in this region (26, 33) have been characterized as
inhibitory and cross-reactive (Table 4). Although further analysis is required, the differences in
function of the mouse and human MAbs could be related to affinity or possibly, that the human
MAbs bind additional sites and do not exclusively recognize the linear epitope centered at
residues G523-D535, as was suggested in previous studies (1, 26).
The neutralizing MAbs J6.36 and J6.103 also mapped to a discontinuous epitope,
requiring residues within the HVR1 (G397, F403, and G406) and the more COOH-terminal
residue R572. Although neutralizing MAbs (9/27 (18, 30) and AP213 (65)) have been mapped to
the HVR1, to our knowledge, MAbs that bind residues at or near R572 have not been identified.
The MAb 9/27 does not block binding of sE2 to CD81 (18, 30) although it did inhibit HCV VLPs
interaction with CD81 (45), suggesting that it also may recognize a conformational or possibly
oligomeric epitope.
The MAb in our study with the greatest inhibitory activity, H77.39, localized to two amino
acids, N415 and N417, that are highly conserved among all HCV genotypes (48, 65). N415 and
N417 were defined previously as possible binding residues for MAbs AP33 and 3/11 (11, 19, 62)
(Table 4). Residue N417 comprises part of a highly conserved N-linked glycosylation site (20, 21)
that is implicated in obscuring antibody-mediated neutralization (27). H77.39, as well as AP33
and 3/11, are thus unique in mapping to an N-linked glycan that is paradoxically hypothesized to
impair antibody recognition.
To relate binding epitopes to function, MAbs were tested for their ability to inhibit sE2
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engagement with the HCV cognate receptors CD81 and SR-B1. The MAbs J6.36, J6.103, and
H77.16, which recognized residues within the HVR1 as well as the more COOH-terminal region,
blocked sE2-SR-B1 binding. These results are consistent with data suggesting the HVR1
participates in SR-B1 binding (3, 5, 56), and that the HVR1-specific MAb 9/27 inhibits sE2-SR-B1
interactions (5, 56). Although J6.36 did not map to any of the predicted CD81 binding residues
(48), it partially inhibited sE2 binding to CD81. J6.36 could map to additional amino acid residues
(within the CD81 binding site) not identified in our study or steric hindrance could mediate this
partial inhibition. In the recently modeled E2 structure (36), the J6.36 interaction residues lie in
proximity to the HCV D1, which is predicted to contain key CD81 binding residues (36, 48) (Fig
8B). Conversely, H77.31, which potently inhibited CD81 binding and maps to residues (W529,
G530) involved in CD81 binding (48) partially inhibited SR-B1 engagement despite a lack of
contact residues in the HVR1. The inability of J6.103 to inhibit binding to CD81 despite localizing
to the same residues as J6.36 could be explained by overlapping but not identical MAb footprints
or perhaps differences in affinity of interaction.
Only one MAb, H77.39, potently inhibited sE2 binding to both CD81 and SR-B1. Interestingly,
H77.39 did not map to residues within known SR-B1 or CD81 binding regions, suggesting that it
may recognize a site that once occupied, can sterically prevent receptor engagement. This
concept is supported by studies showing that N415 and N417 can obscure the CD81 and SR-B1
binding sites (11, 27). Finally, the E2 model recently proposed by Krey et al predicts that residues
N415-N417 lie at the junction of the HVR1 and D1 (Fig 8B), in proximity to both HVR1 and the
CD81 binding residues located within C and D loops of D1 (36, 48).
Pre- and post-attachment neutralization studies provided additional insight into the
relative potency of MAbs. Studies with distantly related Flaviviruses have shown that MAbs
inhibiting at a post-attachment step tend to have greater inhibitory activity in vitro and in vivo
because they require reduced virion occupancy for neutralization (43, 52, 60, 63, 66). Indeed, our
three most potent MAbs, H77.16, H77.39 and J6.36, neutralized infection in the post-attachment
assay. Nevertheless, J6.103 shared apparent binding epitopes with J6.36, yet did not neutralize
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efficiently when added after attachment. This discrepancy may be explained by J6.36 having
additional amino acid contacts not identified in our study.
MAb binding to conserved residues may not directly predict cross-binding or crossneutralizing capabilities (8 , 59). Despite mapping to highly conserved residues, MAbs H77.31,
J.36 and J6.103 failed to cross-react with any other strains tested, and J6.27 was cross-reactive
with only two of the strains tested. In comparison, MAb H77.16 was highly cross-reactive, but still
did not neutralize heterologous strains. In contrast, H77.39 cross-reacted with genotypes 1-6 and
neutralized chimeric virus representative of all strains except genotype 6. The inability of H77.39
to neutralize the genotype 6 chimeric virus may be explained by the presence of a mutation in
one of the recognition residues, N417T (24). This mutation is rare in natural HCV isolates (11,
48), but was required for adaptation of the HK6a/JFH1 chimera in vitro (24). Mutations at N415
are rare (11, 48) and attenuating in the context of HCV infection (19).
Generation of an HCV vaccine has been impeded by the lack of a structural
understanding of the epitopes on E2 that should be targeted by inhibitory antibodies. Although
direct structural confirmation is necessary, our data suggests the existence of discontinuous
epitopes that are recognized by antibodies that inhibit CD81 and SR-B1 binding. The yeast
surface display antibody mapping data also provides support for a recently proposed structural
model of E2 in which the residues comprising the CD81 binding region lie within a single domain
of b-pleated sheets that contains the HVR1 as an N-terminal extension (36). The epitopes defined
by the MAbs H77.16, J6.36, and J6.103 suggest that the HVR1 might lie in proximity to this
domain, creating a conformational epitope (Fig 8B), which could be a useful target for vaccines
and therapeutic antibodies.
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FIGURE LEGENDS
Table 2.1: Binding of MAbs to HCV E2 from different HCV genotypes.

+++, strong

binding (40-100%) to yeast expressing E2; +, weak binding (15-40%) to yeast expressing E2; -,
no appreciable binding detected. Data is a summary of between 3 and 5 independent
experiments.
Table 2.2: Summary of MAb binding to genotype 1 mutants expressed on the
surface of yeast.

Values shown were obtained by dividing the total fluorescence product

(percent positive population x mean fluorescence intensity) of a mutant for a given MAb by the
total fluorescence product of the wild type E2 for a given MAb. This value was then divided by the
total fluorescence product of a mutant for an oligoclonal MAb pool by the total fluorescence
product of WT E2 for the same olicoglonal pool (to control for E2 binding) and multiplied by 100.
Values in bold indicate complete loss of binding, with reductions in MAb binding greater than or
equal to 80% for a given mutation. Underlined values indicate a partial reduction in binding,
between 50 and 79%. Values italicized, bolded and underlined show enhancement of binding
greater than 500%. The results are the average of three independent experiments for each
mutant and each antibody.
Table 2.3: Summary of MAb binding to genotype 2a mutants expressed on yeast.
Values shown were obtained by dividing the total fluorescence product (percent positive
population x mean fluorescence intensity) of a mutant for a given MAb by the total fluorescence
product of the wild type E2 for a given MAb. This value was then divided by the total fluorescence
product of a mutant for an oligoclonal pool of MAbs by the total fluorescence product of WT E2 for
the oligoclonal pool (to control for E2 binding) and multiplied by 100. Values in bold indicate
complete loss of binding, with reductions in MAb binding greater than or equal to 80% for a given
mutation. Underlined values show partial loss of binding, with a reduction between 50 and 79%.
The results are the average of three independent experiments for each mutant and each
antibody. Poly-protein amino acid numbering was determined by alignment with the H77 strain
using the Sequence Location tool on the Los Alamos HCV database (http://hcv.lanl.gov/cgibin/LOCATE/locate.cgi).
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Table 2.4: Previously characterized neutralizing anti-E2 MAbs with available
mapping information. Summary of previously characterized, neutralizing, anti-E2 MAbs.
Table 2.5: Profile of anti-E2 MAbs. Isotype was determined by ELISA. Cross-reactivity
to other genotypes and binding to different regions of E2 was determined by flow cytometric
analysis of MAb binding to yeast expressing E2 from different genotypes or truncation mutants of
E2, respectively (+++, strong binding (40-100%) to yeast; +, weak binding (15-40%) to yeast; -,
no appreciable binding detected). Neutralizing activity at 50 µg/ml was determined by luciferase
assay for genotype-2 specific MAbs and by FFU reduction assay for genotype-1 specific MAbs.
Figure 2.1: Identification of neutralizing anti-E2 antibodies against HCV. A.
Examples of MAb neutralization as judged by a reduction in the number of FFU using the Biospot
Macroanalyzer. Spot counts are labeled below each well and well numbers are labeled above.
Wells 1 through 8 represent decreasing (3-fold) concentrations of the neutralizing MAb H77.39
(starting concentration of 50 mg/ml). Well 9 shows infection in the absence of MAb, and well 10 is
an uninfected well. Data are representative of three independent experiments performed in
duplicate. B. MAb supernatant was mixed with the H77-JFH1 chimeric HCV for one 1 hour at
37°C and Huh-7.5 cells were infected. Three days later, neutralization was determined by FFU
assay. MAb supernatants that decreased the number of FFU to 40% or less (below the solid
black line) than the negative control MAb (anti-WNV E122), as well as additional selected MAbs,
were purified for testing in full dose-response analysis. Data is pooled from three independent
experiments performed in duplicate. C. Serial dilutions of genotype 1a specific purified MAbs
were mixed with H77-JFH1 chimeric virus and neutralization was assessed. Efficient
neutralization was observed for five (H77.16, H77.28, H77.31, H77.39 and H77.56) genotype 1a
specific MAbs but not for the negative control MAb (data not shown). EC50 values were
calculated after non-linear regression analysis. Data is pooled from of at least three independent
experiments performed in duplicate. D. Increasing concentrations of purified genotype 2a specific
MAbs (J6.36 and J6.103) were mixed with J6-JFH1-JC1-luciferase-expressing virus. At 48 hours,
neutralization was assessed in Huh-7.5 cells by monitoring luciferase expression. EC50 values
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were calculated after non-linear regression analysis. Data is pooled from at least three
independent experiments performed in duplicate. In this Figure, all error bars represent the
standard error of the mean.
Figure 2.2: Identification of MAbs that bind heterologous HCV genotypes using
yeast display of E2 protein. The E2 ectodomain gene from six strains corresponding to HCV
genotypes 1-6 was cloned into the PYD1 vector and expressed on the surface of yeast (see
Materials and Methods). Yeast expressing HCV E2 were incubated with MAb supernatants and
binding was assessed by flow cytometry. Representative histograms from all neutralizing MAbs
(H77.16, H77.28, H77.31, H77.39, H77.56, J6.27, J6.36 and J6.103; solid black histograms) and
negative control MAb (WNV E16; unfilled gray histograms) are depicted. Data is representative of
three independent experiments.
Figure 2.3: MAb neutralization of heterologous HCV genotypes. MAbs that were
generated against (A) genotype 1a or (B) genotype 2a E2 proteins were tested for their ability to
neutralize infection of virus from the heterologous genotype. Purified J6 or H77 MAbs (50 mg/ml)
were pre-incubated at 37°C with H77-JFH1 (genotype 1a) or J6-JFH1-JC1 (genotype 2a) virus,
respectively, and neutralization was assessed as described in Figure 1. C-E. EC50 analysis was
performed with (C) J6.27 MAb and H77-JFH1 virus (■) or J6-JFH1-JC1 virus (○) or (D) H77.39
MAb and J6-JFH1-JC1 virus (○) or (E) H77.39 MAb and H77C/JFH1 (■), S52/JFH1 (▼),
ED43/JFH1 (♦), SA13/JFH1 (●) and HK6a/JFH1 (□) chimeric viruses. Graphs represent pooled
data from at least three independent experiments performed in duplicate (A-D) or two
independent experiments performed in triplicate (E), and error bars represent the standard error
of the mean.
Figure 2.4: Pre- or post-attachment neutralization. A-D. To determine whether MAbs
neutralize HCV infection at a post-attachment step, Huh-7.5 cells were pre-chilled at 4°C and 480
FFU of (A) genotype 1a (H77-JFH1) or (B) genotype 2a (J6-JFH1-JC1) virus was added to each
well for 1 hour at 4°C. After three washes with 4°C DMEM, saturating concentrations of MAbs (50
mg/ml) were added for 1 hour at 37°C and the neutralization assay completed. In comparison, a
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standard pre-incubation neutralization test was performed at 37°C, in which (C) genotype 1a virus
or (D) genotype 2a virus and MAb were pre-incubated at 37°C prior to addition to cells. Data
shown are the average of three independent experiments, with error bars representing standard
error of the mean. Statistically significant difference in neutralization are compared to infection in
the presence of a negative control MAb (WNV E16): *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
E. To confirm the ability of H77.39 to neutralize infection at both pre-and post-attachment steps, a
dose response curve was performed under both pre-and post-attachment conditions as described
above using H77/JFH1 virus. Solid squares (■) represent pre-attachment data and clear squares
(□) represent post-attachment data. Graphs represent pooled data from at least three
independent experiments performed in duplicate, and error bars represent the standard error of
the mean.
Figure 2.5: Inhibition of sE2 binding to CD81 and SR-B1 by neutralizing MAbs. A.
Verification of ectopic CD81 and SR-B1 receptor expression on CHO cells. CHO-CD81 or CHOSR-B1 cells were incubated with either mouse anti-hCD81 or rabbit-anti-hSR-B1 (black
histograms) or an irrelevant MAb (unfilled gray histograms) for 30 minutes on ice. Cells were
washed, incubated with the appropriate secondary antibodies, and processed by flow cytometry.
B-C. Binding of (B) genotype 1a (H77) E2 or (C) genotype 2a (J6) E2 to CHO-CD81 and CHOSR-B1 but not WT CHO cells. CHO-CD81 or CHO-SR-B1 (solid black histograms) or WT CHO
(unfilled gray histograms) cells were incubated with sE2 and binding was assayed by flow
cytometry. Data are representative of at least three independent experiments. D. Assessment of
inhibition of sE2 binding to CHO-CD81 or CHO-SR-B1 cells by neutralizing MAbs. sE2 was preincubated with neutralizing MAbs, added to CHO cells, and binding detected by flow cytometry.
Examples of MAbs that inhibit sE2 binding to CD81 preferentially (H77.31), to both CD81 and SRB1 (H77.39), or only to SR-B1 (J6.103), as well as a negative control MAb (WNV E16) are shown.
Histograms are representative of three individual experiments. Solid black histograms represent

sE2 binding in the presence of MAb, red histograms represent sE2 binding in the absence of
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MAb, and shaded gray histograms represent sE2 binding to CHO WT cells. E. Graphical
representation of sE2 binding to CHO-CD81 and CHO-SR-B1 cells in the presence of neutralizing
MAbs. Values were determined by dividing the fluorescence quotient (mean fluorescence
intensity x percent positive cells) for E2 binding in the presence of a neutralizing MAb by the
fluorescence quotient of sE2 binding to either CHO-CD81 or CHO-SR-B1 cells alone. Asterisks
represent statistically significant difference in sE2 binding compared to the negative control MAb,
WNV E16: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. Error bars represent the standard error of
the mean. Data are pooled from three independent experiments.
Figure 2.6: Mapping of anti-E2 antibodies using COOH-terminal truncation
mutants. A. Scheme of E2 truncations used for mapping. cDNA containing region I (aa 384-520
and aa 384-518 in E2 of genotypes 1a and 2a, respectively) I and II (aa 384-605 and 384-603 in
E2 of genotypes 1a and 2a, respectively), and the full length ectodomain (aa 384-664) were
displayed on the surface of yeast. B. MAb supernatants were incubated with yeast and assessed
for binding by flow cytometry. Neutralizing MAbs binding to regions I (H77.16, H77.39, J6.36, and
J6.103), II (H77.28, H77.31, and J6.27), and full-length E2 ectodomain (H77.56) are shown. Solid
black histograms depict binding of HCV-specific MAbs and gray, unfilled histograms represent
binding of a negative control MAb (WNV E16).

Histograms are representative of three

independent experiments.
Figure 2.7: Epitope localization of anti-HCV MAbs. Binding of neutralizing MAbs to
yeast expressing E2 protein variants. A. Flow cytometry histograms of wild type and loss-ofbinding genotype 1a E2 variants (G406D, G406S, N410Y, I411N, N415Y, N417T, W529R,
G530A, D533N, R543G, C552S, and G406S + G530A). Representative histograms are shown for
the MAbs H77.14, H77.16, H77.28, H77.31, H77.39, H77.56 and WNV E16 (negative control)
with WT H77 E2 and each of the variants. Data shown are representative of three independent
experiments. Red arrows indicate >80% loss-of-binding of a specific MAb for a given variant.
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B. Flow cytometry histograms of wild type and loss-of-function genotype 2a E2 variants (G397E,
F403L, G406C, A524V, W529C, R572S, H621L and G397E+R572S) with individual neutralizing
MAbs. Representative histograms are shown for the MAbs J6.27, J6.36, J6.101, J6.103 and
WNV E16 (negative control) with the wild type E2 and each of the variants. Data shown are
representative of three independent experiments. Arrows indicate >80% loss-of-binding of a
specific MAb for a given variant.
Figure 2.8: Localization of MAb binding residues on E2.

A.

Alignment of E2

sequences from HCV genotypes 1-6 with superimposed mapping of MAb binding residues. The
sequences of E2 from strains representative of the different genotypes (genotype 1a, H77;
genotype 2a, J6; genotype 3a, UKN 3; genotype 4a, UKN4a; genotype 5a, SA513; genotype 6a,
UKN 6) used in the yeast mapping studies (Fig 2) were aligned. Colored boxes and symbols
were used to highlight neutralizing MAb binding residues as follows: red boxes, J6.36 and J6.103;
purple boxes, H77.39; blue underscoring, H77.16; green boxes, J6.27; pink circles, H77.31;
orange box, H77.28; yellow box, H77.56. B. Putative model of structure of the E2 protein with
MAb binding regions highlighted. A scheme depicting a possible E2 structure was adapted from
Krey et al. (36) to highlight regions involved in MAb recognition. N-linked glycosylation residues
are labeled in green and amino acids numbered in black at intervals. b-sheets in D1 are labeled
as previously described (36). MAb binding regions are highlighted by colored circles as follows:
red circles, J6.36 and J6.103; purple circle, H77.39; light blue circles, H77.16; green circle, J6.27;
pink circle, H77.31; orange circle, H77.28; yellow circle, H77.56. C. Summary of neutralizing
MAbs described in this study. EC50 values (neutralization against homologous virus), crossreactivity to E2 from different genotypes, inhibition of binding to CD81 and SR-B1, reactivity with
different regions of E2, and loss of binding residues are listed. MAb names are color-coded to
correspond to panels A and B.
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Table 2.1: Binding of MAbs to HCV E2 from different HCV genotypes
MAb

Genotype

Genotype

1a(H77)

Genotype

2a(J6)

Genotype

3a(UKN 3)

Genotype

4a(UKN4)

Genotype

5a(SA13)

6a(UKN6)

J6.1

+++

+++

+++

+++

+++

+++

J6.2

+

+++

+++

+++

-

-

J6.6

+

+++

+

-

-

-

J6.7

+++

+++

+++

+

+++

+++

J6.8

+

+++

-

-

-

-

J6.9

+++

+++

-

-

+++

-

J6.12

+++

+++

+++

+++

-

-

J6.13

-

+++

-

-

-

-

J6.14

+++

+++

+++

+

+

+++

J6.15

-

+++

+++

+++

+++

+++

J6.16

+++

+++

+++

-

+++

-

J6.21

+++

+++

-

-

-

-

J6.23

+

+++

-

-

-

-

J6.25

-

+++

-

-

-

-

J6.27

+++

+++

+++

-

-

-

J6.30

+++

+++

+++

+++

+++

+++

J6.33

+++

+++

+++

+++

+++

+++

J6.34

+++

+++

+

+

+++

+

J6.36

-

+++

-

-

-

-

J6.39

+++

+++

+++

-

-

-

J6.40

-

+++

+

-

-

-

J6.42

+

+++

+++

+++

-

-

J6.48

-

+++

-

-

-

-

J6.49

-

+++

-

-

-

-

J6.51

+

+++

+

+++

-

-

J6.56

+++

+++

+++

+

+++

+++

J6.58

+++

+++

+++

+/-

+++

-

J6.60

-

+++

-

-

-

+++

J6.62

+++

+++

+++

+

+++

+

J6.67

+++

+++

+

-

+++

-

J6.68

+

+++

-

-

-

-

J6.75

+++

+++

+++

+++

+++

+++

J6.76

-

+++

-

-

-

-

J6.81

+++

+++

+++

-

+++

-

J6.85

-

+++

+++

+++

+++

+++

J6.86

+

+++

+++

+++

-

-

J6.91

+

+++

-

-

-

-

J6.98

-

+++

+

+++

-

-

J6.99

-

+++

-

-

-

+

J6.101

+++

+++

+

+++

-

+++
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J6.103

-

+++

-

-

-

-

H77.1

+++

-

-

-

-

-

H77.7

+++

+++

+++

+++

+++

+++

H77.8

+++

-

-

-

-

-

H77.9

+++

-

-

-

-

-

H77.11

+++

-

-

-

-

-

H77.12

+++

+++

-

-

+++

-

H77.13

+++

-

-

-

-

-

H77.14

+++

-

-

-

-

-

H77.16

+++

+++

+++

+++

+++

+++

H77.17

+++

-

-

-

-

-

H77.18

+++

-

-

-

+

-

H77.19

+++

-

-

-

-

-

H77.22

+++

-

-

-

-

-

H77.23

+++

-

-

-

-

-

H77.27

+++

+++

-

-

+

-

H77.28

+++

+++

-

-

+

-

H77.29

+++

+++

-

-

+

-

H77.30

+++

-

-

-

-

-

H77.31

+++

-

-

-

-

-

H77.32

+++

+

+++

-

+++

-

H77.33

+++

-

-

+++

-

-

H77.34

+++

-

-

-

-

-

H77.35

+++

-

-

-

-

-

H77.36

+++

+++

+++

+++

+++

+++

H77.37

+++

-

-

-

+++

-

H77.38

+++

-

-

-

-

-

H77.39

+++

+++

+++

+++

+++

+++

H77.42

+++

-

-

-

+

-

H77.43

+++

-

-

-

-

-

H77.44

+++

-

-

-

+++

-

H77.45

+++

-

-

-

-

-

H77.46

+++

-

-

-

+++

-

H77.47

+++

+++

-

-

-

-

H77.50

+++

-

-

-

-

-

H77.53

+++

-

-

-

+++

-

H77.55

+++

-

-

-

+++

-

H77.56

+++

+++

+++

+++

-

+++
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Table 2.2. Summary of MAb binding to genotype 1 mutants expressed on the surface of
yeast

MAbs

G397E

F403L

G406C

S440P

Y443C

A524V

W529C

E531V

R572S

H617L

G397E+R572S

J6.1

71

97

100

100

83

83

100

88

100

100
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J6.2

71

100

16

100

93

73

20

68

42

6

56

J6.6

64

100

26

41

100

6

4

69

100

100

100

J6.15

100

100

100

75

85

66

13

34

100

100

79

J6.16

100

100

100

76

100

80

100

86

100

100

100

J6.27

74

67

100

90

95

<1

<1

77

83

100

80

J6.30

85

100

100

100

75

58

88

82

100

3

100

J6.36

100

<1

<1

60

95

80

100

100

100

100

<1

J6.39

94

91

100

100

83

100

3

63

100

100

81

J6.40

98

100

32

32

100

75

63

65

40

15

80

J6.60

51

58

100

<1

<1

65

90

81

70

73

77

J6.75

100

100

100

100

100

100

100

100

100

100

100

J6.85

100

100

100

100

91

72

10

27

100

100

80

J6.101

83

100

43

100

100

100

57

91

82

3

50

J6.103

100

2

<1

26

100

100

100

100

100

100

<1
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Table 2.3: Summary of MAb binding to genotype 2a mutants expressed on the surface of
yeast
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Table 2.4: Previously characterized neutralizing anti-E2 MAbs with available mapping
information
MAb name

Binding residues

AP33

Source of
MAb
Mouse

3/11

Rat

N415, W420, H421

9/27

Rat

396-407

11/20

Rat

436-447

7/16b

Rat

436-447

2/69a

Rat

432-443

2/64a

Rat

524-531

1/39

Rat

432-443

CBH-5

Human

CBH-7

Human

G523, P525, G530,
D535, N540
N540, W549

HCV-1

1:7

HuMAb
mice
HuMAb
mice
Human

A8

Human

AR2A

Human

AR3A

Human

AR3B

Human

AR3C

Human

AR3D

Human

e137

Human

95-2

L413, N415, G418,
W420

L413, W420
L413, W420
G523, T526, Y527,
W529, G530, D535
G523, T526, Y527,
W529, G530, D535
N540A
S424, G523, P525,
G530, D535, N540
S424, G530, D535
S424, P525, G530,
D535, N540
S424, G530
T416, W420, W529,
G530, D535

Neutralization of
HCVpp?
Yes; all genotypes

Neutralization of
HCVcc?
Yes; >80%
neutralization with
50ug/ml MAb
N/D

References

N/D

(18, 30, 45)

N/D

(18, 30)

N/D

(18, 30)

N/D

(18, 30)

N/D

(18, 30)

N/D

(18, 30)

Yes

(26, 47)

Yes

(26, 47)

N/D

(9)

N/D

(9)

Yes

(33)

Yes; all genotypes

Yes

(33)

Yes; genotypes 1,
2, 4, and 5
Yes; genotypes 1,
2, 4, and 5
Yes; genotypes 1,
2, 4, and 5
Yes; genotypes 1,
2, 4, and 5
Yes; genotypes 1,
2, 4, and 5
Yes; genotypes 1,
2, and 4

No

(37)

Yes

(37)

Yes

(37)

Yes

(37)

Yes

(37)

Yes

(49)

Yes; genotypes 1,
2, 4, 5, and 6 by
>50%
Yes; genotype 1 by
>99%
Yes; genotype 1 by
>99%
Yes; neutralized
HCVpp
representative of
genotype 1 by
>99%
Yes; genotype 1 by
>99%
Yes; genotype 1 by
40%
Yes; genotype 1 by
20%
Yes; all genotypes
>40%
Yes; genotypes 1,
2 and 4 by >20%
Yes; genotypes 1,
2, 3, and 4
Yes; genotypes 1,
2, 3, and 4
Yes; all genotypes
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(19, 45, 46, 62)
(18, 30, 45, 62)

Table 2.5: Profile of anti-E2 MAbs
MAb

Isotype

Crossreactivity

Binding to E2

Binding to E2

Binding to Full

region I

region II

length E2

% Neutralization at
50 µg/ml

J6.1

IgG1

1, 3, 4, 5, 6

-

-

+++

None

J6.2

IgG1

1, 3, 4

-

-

+++

None

J6.6

IgG1

1, 3

-

+++

+++

None

J6.7

IgG1

1, 3, 4, 5, 6

-

-

+++

None

J6.8

IgG1

1

-

+++

+++

None

J6.9

IgG1

1, 5

-

-

+++

None

J6.12

IgG1

1, 3, 4

-

-

+++

None

J6.13

IgG1

-

-

+++

+++

None

J6.14

IgG1

1, 3, 4, 5, 6

+++

+++

+++

None

J6.15

IgG1

2, 3, 4, 5, 6

-

-

+++

None

J6.16

IgG1

1, 3, 5

-

+++

+++

None

J6.21

IgG1

1

-

-

+++

None

J6.23

IgG1

1

-

+++

+++

None

J6.25

IgG1

-

-

-

+++

None

J6.27

IgG1

1, 3

-

+++

+++

None

J6.30

IgG1

1, 3, 4, 5, 6

-

-

+++

None

J6.33

IgG1

1, 3, 4 ,5, 6

-

-

+++

None

J6.34

IgG1

1, 3, 4, 5, 6

-

-

+++

None

J6.36

IgG2b

-

+++

+++

+++

95%

J6.39

IgG1

1, 3

-

+++

+++

None

J6.40

IgG1

3

-

-

+++

None

J6.42

IgG1

1, 3, 4

-

-

+++

None

J6.48

IgG1

-

-

-

+++

None

J6.49

IgG1

-

-

-

+++

None

J6.51

IgG1

1, 3, 4

-

-

+++

None

J6.56

IgG1

1, 3, 4, 5, 6

+++

+++

+++

None

J6.58

IgG1

1, 3, 4, 5

-

-

+++

None

J6.60

IgG1

6

+++

+++

+++

None

J6.62

IgG1

1, 3, 4, 5

-

-

+++

None

J6.67

IgG1

1, 3, 5

-

-

+++

None

J6.68

IgG1

1

-

+++

+++

None

J6.75

IgG1

1, 3, 4, 5, 6

-

-

+++

None

J6.76

IgG1

-

-

-

+++

None

J6.81

IgG1

1, 3, 5

-

-

+++

None

J6.85

IgG1

3, 4, 5, 6

-

+++

+++

None

J6.86

IgG1

1, 3, 4

-

-

+++

None

J6.91

IgG1

1

-

+++

+++

None

J6.98

IgG1

3, 4

-

-

+++

None

J6.99

IgG1

6

+++

+++

+++

None

J6.101

IgG1

1, 3, 4, 6

-

-

+++

None

65

J6.103

IgG1

-

+++

+++

+++

82%

H77.1

IgG1

-

-

-

+++

None

H77.7

IgG1

2, 3, 4, 5, 6

-

+++

+++

None

H77.8

IgG1

-

-

-

+++

None

H77.9

IgG1

-

-

-

+++

None

H77.11

IgG1/2a

-

+++

+++

+++

None

H77.12

IgG1

2, 5

-

+++

+++

None

H77.13

IgG2a

-

-

+++

+++

None

H77.14

IgG2a

-

+++

+++

+++

None

H77.16

IgG2a

2, 3, 4, 5, 6

+++

+++

+++

97%

H77.17

IgG2a

-

+++

+++

+++

None

H77.18

IgG1

5

-

-

+++

None

H77.19

IgG2a

-

+

+++

+++

None

H77.22

IgG1

-

-

-

+++

None

H77.23

IgG2b

-

+++

+++

+++

None

H77.27

IgG1

2, 5

-

+++

+++

None

H77.28

IgG1

2, 5

+++

+++

+++

69%

H77.29

IgG1

2, 5

-

-

+++

None

H77.30

IgG1

-

-

-

+++

None

H77.31

IgG2a

-

-

+++

+++

52%

H77.32

IgG1

2, 3, 5

-

-

+++

None

H77.33

IgG1

4

+++

+++

+++

None

H77.34

IgG2b

-

-

-

+++

None

H77.35

IgG1

-

+++

+++

+++

None

H77.36

IgG1

2, 3, 4, 5, 6

-

+++

+++

None

H77.37

IgG1/2b

5

-

-

+++

None

H77.38

IgG2a

-

-

+++

+++

None

H77.39

IgG1

2, 3, 4, 5, 6

+++

+++

+++

100%

H77.42

IgG1

5

-

-

+++

None

H77.43

IgG2b

-

-

-

+++

None

H77.44

IgG1

5

-

+++

+++

None

H77.45

IgG1

-

-

-

+++

None

H77.46

IgG2a

5

-

-

+++

None

H77.47

IgG1

2

-

-

+++

None

H77.50

IgG1

-

-

-

+++

None

H77.53

IgG1

5

-

-

+++

None

H77.55

IgG2a

5

-

-

+++

None

H77.56

IgG1

2, 3, 4, 6

-

-

+++

63%

66
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68

69
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Chapter 3

Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and
temperature

This chapter has been submitted as:
Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. Hepatitis C virus epitope
exposure and neutralization by antibodies is affected by time and temperature. Submitted to
Virology, Sept 2011.
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ABSTRACT
A recent study with flaviviruses suggested that structural dynamics of the virion impact
antibody neutralization via exposure of ostensibly cryptic epitopes. To determine whether this
holds true for the distantly related hepatitis C virus (HCV), whose neutralizing epitopes may be
obscured by a glycan shield, apolipoprotein interactions, and the hypervariable region on the E2
envelope protein, we assessed how time and temperature of pre-incubation altered monoclonal
antibody (MAb) neutralization of HCV. Notably, several MAbs showed increased inhibitory activity
o

when pre-binding was performed at 37 C or after longer pre-incubation periods, and a
corresponding loss-of-neutralization was observed when pre-binding was performed at 4°C. A
similar profile of changes was observed with acute and chronic phase sera from HCV-infected
patients. Our data suggest that time and temperature of incubation modulate epitope exposure on
the conformational ensembles of HCV virions and thus, alter the potency of antibody
neutralization.

	
  

83
	
  

INTRODUCTION
Hepatitis C virus (HCV) is a hepatotropic virus that chronically infects ~170 million people
worldwide and results in an increased risk of hepatocellular carcinoma and liver cirrhosis. Until
recently, the only available treatment was a combined regimen of ribavirin and pegylated
interferon-α, which resulted in sustained virologic response in only ~50% of individuals (6). The
addition of newly approved NS3 protease inhibitors (boceprevir and telaprevir) to this regimen
has improved response rates, although an increase in side effects was noted (1, 24, 50, 66).
Given that long-term pharmacological therapy may have limitations in curing HCV-infected
individuals, especially in resource-poor parts of the world, there is renewed interest in the
development of preventative or even therapeutic vaccines (58). Vaccine development, however,
has been hampered by the absence of a tractable small animal model of HCV infection and an
incomplete understanding of the correlates of antibody protection in vivo.
HCV is a positive stranded 9.6 Kb RNA virus in the Hepacivirus genus of the Flaviviridae
family, which also includes globally important pathogens such as Dengue (DENV), West Nile
(WNV), yellow fever, and Japanese encephalitis viruses (33). HCV is translated from an internal
ribosome entry site (IRES) as a single polyprotein and is cleaved by viral and host proteases into
three structural (core, E1, E2) proteins, the ion channel p7, and six non-structural proteins (NS2,
NS3, NS4A, NS4B, NS5A, and NS5B) (34). Cell culture-produced HCV forms smooth, spherical,
enveloped particles that are ~60 nm in diameter (16, 65) with E1 and E2 on the surface. Despite
recent predictive models suggesting that HCV E2 protein assumes a three domain structure
similar to the E protein of flaviviruses (27), E2 is distinguished from flavivirus E protein by its nine
intramolecular disulfide bonds (27), covalent linkage to E1 (62), 11 N-linked glycosylation sites
(17, 18), and two hypervariable regions (HVR1 and HVR2) (37, 64). E2 contains binding sites for
both the CD81 and SR-B1 receptors (49, 55),	
   and MAbs that block CD81-E2 and SR-B1-E2
interactions prevent infection in cell culture (4, 21, 30, 46, 47, 54, 59).
The role of the humoral response in protection against HCV infection remains
controversial, although several studies have suggested that anti-E2 antibodies can limit infection
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in vivo (14, 23, 30). Antibodies elicited by immunization of chimpanzees with HCV envelope
proteins partially protect against viral challenge (15, 38, 51). In the setting of acute infection in
humans, antibody responses against the HCV envelope proteins are delayed, with less than 33%
of subjects developing neutralizing antibodies at six months (40). Most humans generate a
neutralizing antibody response that correlates with viral clearance although chronically infected
patients also produce neutralizing antibodies (35). Thus, the presence of neutralizing antibodies
in serum does not directly correlate with a viral clearance phenotype. Possible explanations for
this phenomenon include: (i) HCV E2 interaction with high-density lipoproteins (HDL) shield
virions from recognition by neutralizing antibodies that are present in serum (3, 13, 29), (ii)
different functional classes of neutralizing antibodies have distinct inhibitory mechanisms and
potencies or (iii) immune pressure drives rapid viral escape from the host humoral response (11,
63)
Antibody-mediated neutralization of Flaviviridae family members requires engagement by
antibodies with a stoichiometry that exceeds a particular threshold (reviewed by (10)). The
number of antibodies bound to the virus particle is governed by the avidity of the antibody for its
cognate epitope on the virion, and the number of times that epitope is displayed accessibly on the
virion. Antibody avidity determines the fraction of accessible antibody epitopes bound by antibody
molecules at a given concentration of antibody (12, 26). For flaviviruses such as WNV, quasiicosahedral symmetry on the virion surface results in differential display of epitopes, such that the
minimum occupancy requirement for a given antibody may never be achieved (reviewed in (9)).
Despite this, MAbs that bind to epitopes that are predicted as cryptic can still neutralize infection
(36, 43, 57). Recent studies with WNV and DENV have demonstrated that cryptic epitopes can
become exposed with increased antibody-virus pre-incubation time or temperature, presumably
due to enhanced viral motion (10).
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Although HCV E2 is predicted to have a structure similar to flavivirus E proteins (27) and
the virion is hypothesized to have an analogous icosahedral organization (65), the association of
the virus with apolipoproteins (39, 45), the glycan shield and additional intramolecular and
intermolecular disulfide linkages on E2 could impose limits to viral motion and epitope
accessibility. To gain more insight into the variation of epitope exposure on the surface of HCV,
we studied the effects of temperature and time of antibody-virus incubation on neutralization of
HCV using a previously characterized panel of MAbs (54).
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MATERIALS AND METHODS
Cells and viruses. Huh7.5 cells were cultured as previously described (Sabo et al.,
2011). Virus stocks of the HJ3-5 H77/JFH1 chimeric virus and the luciferase expressing
J6/JFH1/Jc1 virus were generated as described (Sabo et al., 2011) and concentrated using
Amicon Ultra tubes (Milipore) with 100 kDa cut-off membranes.
Quantitative RT-PCR. RNA was extracted using the RNA Easy Mini kit (Qiagen). qRTPCR was performed using the Taq-Man one-step RT-PCR master mix reagents (Applied
Biosystems) and the following primers and probe located in the 3’ untranslated region (3’ UTR):
Forward primer: 5’-GGC TCC ATC TTA GCC CTA GTC-3’; Reverse primer: 5’-AGT ATC GGC
ACT CTC TGC AGT-3’; and probe 6FAM5’-CGG CTC ACG GAC CTT TCA CAG CT3’. Data was
analyzed using a 7500 Fast Real-Time PCR system (Applied Biosystems) with 7500 Software
(Applied Biosystems, v 2.0.5).
Antibodies. The anti-E2 MAbs H77.31, H77.39, H77.46, J6.27, J6.36, and J6.103 were
described previously (Sabo et al., 2011). The anti-CD81 antibody (JS-81) was purchased from
BD Biosciences. WNV-E16 has been extensively described (Nybakken et al., 2005; Oliphant et
al., 2005). HCV immune sera from infected patients (AA, H06, S18, S19, S112, and S154,) have
been described previously (Cox et al., 2005; Osburn et al., 2010; Scheel et al., 2008). Negative
control serum (SM) was obtained from an HCV-naive donor.
Neutralization assays. Neutralization of the chimeric H77/JFH1 virus containing the
genotype 1 structural proteins was assessed by focus forming unit (FFU) reduction assay. Serial
2

three-fold dilutions of antibody were pre-incubated with 3.2 x 10 FFU of HCV for one hour at
37°C and added to a monolayer of Huh7.5 cells in a 96-well plate coated with poly-L lysine
(Sigma). Three days later, cells were fixed with ice-cold methanol (0°C) and foci quantified as
previously described (Sabo et al., 2011) using a S5 Biospot Macroanalyzer (Cellular
Technologies Ltd).
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Neutralization of the genotype 2 J6/JFH1/Jc1 virus was determined by luciferase assay
as previously described (Sabo et al., 2011). Serial three-fold dilutions of antibody were pre2

incubated with 5 x 10 FFU of virus for one hour at 37°C and added to monolayers of Huh7.5
cells in a 96-well black bottom plate (Corning). Luciferase expression was detected after 48 hours
as previously described (Sabo et al., 2011), according to the manufacturer’s instructions.
To assess the role of temperature on MAb activity, neutralization assays were modified
as follows. Serial dilutions of antibody were pre-incubated with HCV (multiplicity of infection (MOI)
of 0.05) for one hour at 4°C, 37°C, or 40°C. In most experiments, antibody-virus mixtures were
added to monolayers of Huh7.5 cells and infection assessed as described above. In some
experiments with H77.39 and J6.36, antibody-virus mixtures were chilled, added to pre-chilled
monolayers of Huh7.5 cells, and “spinoculated” at 1500 rpm for 45 minutes at 4°C. After three
washes with ice cold DMEM containing 10% FBS, the temperature was raised to 37°C, and
infectivity assessed by luciferase assay or FFU assay 48 hours or 72 hours later, respectively.
Relative infectivity was determined after comparison to infectivity of HCV incubated at the same
temperature in parallel in the absence of antibody.
To assess the role of incubation time on antibody potency, neutralization assays were
modified as follows. Serial dilutions of antibody were pre-incubated with HCV at an MOI of 0.05
for one hour at 37°C to achieve baseline neutralization. Antibody-virus mixtures were then either
directly added to monolayers of Huh7.5 cell or incubated for an additional 2, 4 or 8 hours prior to
infection of cells. Infectivity was assessed by luciferase assay or FFU assay 48 hrs or 72 hrs
later, respectively. Relative infectivity was determined after comparison to infectivity of HCV
incubated under the same conditions in parallel in the absence of antibody.
Immunoprecipitation assays. To assess for changes in MAb-virus binding at different
temperatures, 50 μg/ml of J6.36, negative control MAb (WNV-E16) or medium alone were preincubated with 500 FFU of HCV (J6/JFH1/Jc1) for one hour at 4°C, 37°C or 40°C. Subsequently,
50 μl of protein G Sepharose (Pierce) was added, and the slurry mixed overnight at 4°C.
Sepharose beads were pelleted at 1,000 x g for 2 minutes and washed six times each with 1 ml
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of PBS. Pellets were lysed and RNA was extracted using the Qiamp viral RNA mini kit (Qiagen)
and quantitated by qRT-PCR.
To assess for changes in MAb-virus binding over longer pre-incubation periods the
immunopreciptation assay was modified as follows. MAbs J6.36, WNV-E16 or medium alone
were pre-incubated with 500 FFU of virus for one hour at 37°C and protein G Sepharose was
then added immediately and MAb-virus slurries mixed at 4°C, or MAb-virus mixtures were
incubated for an additional 2, 4, or 8 hours prior to the addition of protein G Sepharose and
transfer to 4°C for mixing. Protein G Sepharose beads were pelleted and washed, and HCV RNA
was extracted and quantified by RT-PCR.
Surface plasmon resonance. The dissociation constants of MAbs H77.39 and J6.36 for
sE2 from genotypes 1a (H77) and 2a (J6) were determined by surface plasmon resonance on a
Biacore T100 instrument. Approximately 500 response units (RU) of H77.39, J6.36 and negative
b

control murine MAb (anti-H2-K ) were covalently coupled to a CM5 sensor chip using amine
chemistry. Increasing concentrations of monomeric, soluble E2 (4 to 1024 nM) were flowed over
the chip in 10mM HEPES, 150 mM sodium chloride, 3 mM EDTA, and 0.005% polysorbate 20
(HBS-EP) at 4°C and 37°C. Binding and dissociation phases were each carried out at 40µl/min
for 180 seconds and the chip was regenerated with 60-second pulses of 0.1 M acetate pH 4.2
and 1 M sodium chloride. All curves were reference subtracted from a flow cell containing the
negative control MAb. Maximum response units were plotted versus concentration and this curve
was fitted to determine KD at each temperature. Antibody J6.36 is not cross-reactive so its affinity
for the genotype 1a sE2 was not determined.	
  
Statistical Analysis. Data was analyzed using GraphPad Prism software, version 4.0.
Comparison of dose response curves was assessed by an F-test. Viral co-immunoprecipitation
assays and EC50 values were analyzed using an unpaired t-test.
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RESULTS
Temperature alters the neutralization potency of anti-E2 MAbs. Studies with distantly
related flaviviruses have suggested that virus “breathing” occurs with increased temperature
allowing differential exposure of epitopes and altered antibody binding and neutralization (10, 36).
As HCV envelope proteins have a greater number (9 versus 6) of intramolecular disulfide bonds
(19, 27), which could rigidify the structure, we initially assessed whether temperature changes
o

altered infectivity of an H77/JFH1 chimeric HCV. A one hour incubation at 4 C, 37°C, 40°C and
o

43 C had relatively small (~2-fold) effects on HCV infectivity (Fig 1A). To assess how
temperature altered MAb-mediated neutralization, serial dilutions of two previously described
neutralizing anti-E2 MAbs, H77.39 and J6.36 (54) were incubated with a genotype 2a
J6/JFH1/Jc1 luciferase reporter virus (54) for one hour at 4°C, 37°C, or 40°C. To ensure that only
the pre-incubation temperature was being evaluated, virus-MAb mixtures subsequently were
bound to cells at 4°C, and unbound virus and MAb was washed away prior to raising the
o

temperature to 37 C for infection. Neutralization by H77.39 and J6.36 was abolished at 4°C and
improved at 40°C (Fig 1B and C). Comparison of the EC50 values at 37°C and 40°C also was
statistically different (Fig 1B and C, right panels, P < 0.03). As expected, neutralization of HCV
infection was not observed at 4°C, 37°C, or 40°C with the negative control MAb (WNV-E16),
which binds to WNV E protein (data not shown). The effects of temperature on MAb neutralization
could not be attributed to virus aggregation, as enhanced neutralization at higher temperatures
also was observed with Fab fragments (Fig 1D), and the neutralization curves did not show a
characteristic triphasic curve that is reported in studies reporting antibody-virus aggregation (60).
Of note, and in contrast to experiments with intact IgG, we omitted the wash step in Fab fragment
neutralization assays prior to HCV infection, as washing resulted in a complete loss of inhibitory
activity, likely secondary to the loss of avidity and resulting detachment of Fab fragments from the
virion (data not shown). Thus, excess Fab fragments were present beyond the initial incubation
o

o

o

o

(at 4 C or 40 C) period and throughout the experiment (at 37 C), which explains why the 4 C
condition inhibited infection as opposed to that observed with intact H77.39 IgG (Fig 1B).
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MAb-virus but not E2 binding is reduced at lower temperatures. To assess whether
the temperature-dependent difference in MAb neutralization of HCV reflected a change in
affinity, the KD of antibody interaction with soluble E2 ectodomain (sE2) was measured at
4°C and 37°C by surface plasmon resonance (SPR). Monovalent affinities were calculated
using steady-state analysis between genotype 1a (H77) and genotype 2a (J6) sE2 and
H77.39, and genotype 2a (J6) sE2 and J6.36. Notably, the KD values were not substantially
different at 4°C and 37°C (Table 1). As no appreciable dissociation was observed between
sE2 and immobilized H77.39 and J6.36 MAb, kinetic parameters were not defined although
a qualitative assessment indicated extremely long half-lives at both temperatures (Fig 2A
and B). These data suggest that the altered MAb neutralization profiles at different
temperatures were not due to large-scale effects on E2 binding. Consistent with this,
prolonged pre-incubation periods at 4°C up to 24 hours only partially affected neutralization by
H77.39 and J6.36 (Fig 2C), and did not alter infectivity of the J6/JFH1/Jc1 luciferase reporter
o

virus in the absence of MAb (Fig 2D). In comparison, pre-incubation of cells at 4 C for one hour
with anti-CD81 MAb efficiently neutralized HCV infection (Fig 2C).
We hypothesized that the greater MAb neutralization potency at higher temperatures was
due to enhanced epitope exposure and capture. To test whether temperature affected the
physical interaction of HCV virions with MAbs, immunoprecipitation studies were performed.
J6/JFH1/Jc1 virus was pre-incubated with J6.36 MAb at 4°C, 37°C, or 40°C for one hour, virusMAb complexes were immunoprecipitated with protein G Sepharose, and levels of viral RNA
were analyzed by qRT-PCR. As expected, in all cases, greater amounts of HCV were
immunoprecipitated by J6.36 MAb than the negative control WNV-E16 MAb (Fig 3A),
establishing the specificity of the assay. Significantly more virus was precipitated when the prebinding step was performed at 37°C or 40°C compared to 4°C (Fig 3A, P < 0.01). Despite the
enhanced MAb neutralization at 40°C relative to 37°C (see Fig 1), we did not observe a statistical
difference (P > 0.2) in virus precipitated by J6.36 MAb after pre-binding at 37°C compared to
40°C; this apparent discrepancy could reflect the slight decrease in stability of virus at 40°C,
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which is not accounted for in this experiment.
Increased incubation time at 37°C enhances MAb-virus binding and neutralization.
Increasing the pre-incubation period also can enhance MAb potency, possibly due to changes in
epitope accessibility as the virus samples alternate ensembles of conformations over time (10).
To assess whether longer incubation times augmented MAb neutralization of HCV, serial dilutions
of H77.39 and J6.36 MAbs were incubated for one hour at 37°C to achieve baseline equilibrium
binding, and MAb-virus mixtures were either added immediately to Huh7.5 cells (time 0) or
incubated for an additional 2, 4 or 8 hours prior to infection. Increasing the pre-incubation period
consistently improved neutralization potency (Fig 4A and 4B), with a significant reduction in
EC50 values occurring after 8 hours of pre-incubation (Fig 4C and 4D, P < 0.05). To determine
whether this effect was due to enhanced MAb-virus binding, complexes were formed for up to 8
hours prior to immunoprecipitation, and viral RNA was quantified by qRT-PCR. Notably, the
amount of virus precipitated was increased after 2, 4 and 8 hours of additional pre-incubation at
37°C (Fig 4E, P < 0.05).
Increased incubation time and temperature broadly improves antibody function
against HCV. MAbs J6.36 and H77.39 were mapped previously to residues within and adjacent
to the hypervariable region 1 (HVR1) on the E2 protein (54). To determine whether temperature
and time-dependent effects also altered neutralization of MAbs mapping to different sites with
distinct potencies, we tested a panel of neutralizing and non-neutralizing MAbs for functional
changes with increased pre-incubation temperature (40°C) or time (12 hours) (Fig 5). The most
potent of the additional MAbs tested, H77.16, localizes to residues in the HVR1 (G406, N410,
I411) and the CD81 binding region (G530) (54), and showed enhanced neutralization with
changes in temperature and time during pre-incubation. This improved activity was reflected by a
shift in neutralization curves (F test, P < 0.0001) and EC50 values (unpaired t-test, P < 0.01) (Fig
5A). In comparison, the more weakly neutralizing MAbs J6.27 and H77.31, which map to residues
in the CD81 binding region, or J6.103, which maps to the HVR1 and the intergenotypic variable
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region (27, 37, 54), showed little enhancement of neutralization under the conditions tested (Fig
5B, P > 0.2). The only non-neutralizing MAb tested showing improved neutralization with
increased temperature or time was H77.46 (Fig 5C, P < 0.001).
Neutralization potency of immune sera from HCV-infected patients is improved by
incubation at higher temperature and prolonged time. To further assess the relevance of
increased temperature or incubation time on antibody neutralization, we analyzed its impact on
polyclonal antibody from sera from acute or chronically HCV-infected patients. Enhanced
neutralization after pre-incubation at 40°C for one hour or 37°C for 12 hours was observed with
sera from acutely infected patients with genotype 1 (S154) or chronically infected individuals with
genotype 1 (S112, S18, S19, H06) and genotype 4 (AA) (Fig 6A and B, P < 0.0001, F test). As
expected, no specific increase in neutralization with time or temperature change was observed
with sera from an uninfected individual (SM). Thus, polyclonal anti-HCV antibody present in
immune sera behaved in a manner similar to MAbs of defined specificity with respect to the
effects on neutralization of prolonged time or elevated temperature exposure.
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DISCUSSION
Prior studies with distantly related flaviviruses have established that antibody-mediated
neutralization of infection is modulated by several factors including avidity of binding and the
availability of the epitope on the virion surface (reviewed in (9, 48)). Nonetheless, some
antibodies neutralize infection despite binding epitopes that ostensibly are obscured on the virus,
at least based on contemporary high-resolution structural models (10, 31, 32, 36). This has led to
the concept of virus “breathing” in which structural perturbations on the virion surface allow
antibody to bind cryptic epitopes, a phenomenon that can be promoted by changes in
temperature (10, 32, 36) and time of interaction (10, 53). Although it is closely related to
flaviviruses, it was unclear whether similar principles apply, as HCV contains additional
intramolecular and intermolecular cysteine bonds on its envelope proteins that could rigidify
structure and restrict movement. Indeed, unlike flaviviruses, HCV is resistant to inactivation at low
pH in solution, and does not undergo plasma membrane fusion from without (61). These
observations may be explained by recent evidence suggesting covalent linkage between the
glycoproteins on the virion surface, a feature that would further rigidify the viral structure (62).
Nonetheless, in our study, we showed that increasing the time and temperature of pre-incubation
enhanced neutralization of HCV by monoclonal and polyclonal antibodies, suggesting that
epitope accessibility can change in a manner analogous to that observed with flaviviruses.
Cryo-electron microscopy studies with the related DENV demonstrated that incubation of
o

virions at physiological temperature (37 C) induced alterations in the virion icosahedral structure
(36) that expose cryptic epitopes allowing for antibody binding and neutralization (10). In the
absence of high-resolution structural information on the HCV envelope proteins or virions, we
assessed functionally whether changes in temperature impacted HCV stability or antibody
neutralization, presumably by altering epitope accessibility. As prolonged incubation in solution
o

o

over a range of temperatures (4 to 43 C) only minimally impacted infectivity (see also (7, 25)),
HCV appears relatively stable, suggesting it does not readily undergo irreversible structural
changes. Consistent with this, and in direct contrast to the related flaviviruses, HCV can be stored
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o

at 4 C for several weeks without appreciable loss of infectivity (7) and exposure to a pH 5.0 acidic
solution does not expose domains on the envelope proteins that result in adventitious fusion and
virus inactivation (61). Nonetheless, prolonged time and elevated temperature likely promoted
changes in the ensemble of virion conformations, as significantly different neutralization profiles
were observed with some but not all anti-HCV antibodies. The changes in neutralization at
different temperatures reflect altered epitope exposure and not modified binding kinetics or virion
o

o

aggregation, as SPR experiments showed minimal change in affinity between 4 C and 37 C and
neutralization by monovalent Fab fragments of HCV antibodies also was enhanced at higher
temperatures. Together, with our immunoprecipitation experiments showing that increased
amounts of virus are precipitated at 37°C compared to 4°C, these data suggest that HCV
undergoes some structural perturbations over time, and this results in altered epitope capture and
antibody neutralization.
The CD81-binding site on HCV E2 may be shielded by HVR1 and a subset of N-linked
glycans (N417, N423, N448, and N532), as deletion of HVR1 or site-specific substitutions that
abolish N-liked glycosylation sites augments the inhibitory capacity of antibodies disrupting E2CD81 interactions (2, 22). Because of this, we anticipated that increasing the time and
temperature of interaction would facilitate exposure of antibody epitopes proximal to the CD81
binding site region, resulting in improved neutralizing activity. While we observed enhanced
potency of neutralization by MAbs (H77.16, H77.39 and J6.36) mapping to HVR1 or contiguous
regions, we did not observe this effect for weakly neutralizing MAbs (H77.31 and J6.27) that
localize to the CD81 binding region. The failure to observe enhanced inhibitory activity by E2specific MAbs that interfere with CD81 binding may reflect a requirement for more significant
structural shifts for complete epitope exposure, analogous to the those required to reveal the
CCR5 binding epitope on HIV gp120 (28, 52). Indeed, previous studies have demonstrated that
anti-CD81 antibodies inhibit infection at a post-attachment step, indicating that CD81 is not
completely engaged by the virus directly after attachment (5, 20, 54). Interestingly, the MAb
J6.103 also did not demonstrate enhanced potency, despite mapping to the same residues as a
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MAb that did, J6.36 (54), possibly due to variations in the MAb footprint that are not apparent
from our epitope mapping by yeast surface display; indeed, J6.36 and J6.103 have different
receptor-blocking capabilities (54), suggesting these MAbs are not functionally equivalent.
While many humans develop a neutralizing antibody response that correlates with viral
clearance, chronically infected patients also produce neutralizing antibodies (35). Thus, the
presence of neutralizing antibodies in serum does not directly correlate with a viral clearance
phenotype. Our studies show that elevated temperature modulates the potency of neutralizing
anti-HCV antibodies, a finding that may have implications for an improved understanding of the
correlates of antibody protection for HCV: (i) the inherent neutralizing capacity of antibody in
serum could change substantially depending on assay conditions; and (ii) fever occurs as a
collateral effect of therapy with pro-inflammatory pegylated IFN-α (67). It is tempting to speculate
that the fever response associated with therapy could improve the efficiency of antibody
neutralization.
Generation of a vaccine for HCV in part, has been hampered by the lack of a structural
understanding of the virus. Although direct structural studies of the HCV virion are required to
corroborate our findings, our studies suggest that HCV has a dynamic component analogous to
flaviviruses (10, 36). Nonetheless, portions of CD81 binding region on E2 likely remain shielded,
making this region a challenge for molecular and immunological targeting. Further study and
identification of the host factors that modulate antibody neutralization against HCV will likely
inform strategies to contain and control infection through induction of more potently inhibitory
humoral responses.
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FIGURE LEGENDS
Table 3.1: Kinetic parameters of MAb binding to sE2 at different temperatures.
Estimates of the KD were determined by equilibrium binding fits of E2 to H77.39 and J6.36 at 4°C
and 37°C degrees. Fold difference was calculated by dividing the KD determined for each MAb-E2
pair at 4°C by the KD determined at 37°C.
Figure 3.1: Temperature alters the neutralizing capabilities of anti-E2 MAbs. A.
Chimeric H77/JFH1 HCV was incubated for one hour at the specified temperatures, added to
Huh7.5 cells, the temperature was raised to 37°C, and infectivity assessed 72 hours later by FFU
assay. Results of FFU assays are pooled from three independent experiments performed in
triplicate. Asterisks represent statistically significant differences in infectivity: *, P < 0.05; **, P <
0.01; and ***, P < 0.001. B-D. Serial dilutions of (B) H77.39 MAb, (C) J6.36 MAb, or (D) H77.39
Fab fragments were pre-incubated with J6/JFH1/Jc1 luciferase reporter virus for one hour at
either 4°C (), 37°C (●) or 40°C (). For B and C, MAb-virus mixtures were incubated at the
indicated temperature, chilled, and then added to pre-chilled Huh7.5 cells to allow for attachment.
o

Cells were then washed thrice (removing excess antibody) and the temperature raised to 37 C for
the duration of the assay. For D, Fab-virus mixtures were incubated at the indicated temperature
and then added to pre-chilled Huh7.5 cells to allow for attachment. Infectivity was assessed by
luciferase assay 48 hours later. Dose response curves (left panels) are displayed relative to the
infectivity of HCV pre-incubated at the indicated temperature in the absence of antibody.
Comparison by F-test demonstrated a statistically significant difference between the curves in all
cases (P < 0.001). The EC50 values at 37°C and 40°C were determined by nonlinear regression
analysis and asterisks represent significant differences: *, P < 0.05; **, P < 0.01; and ***, P <
0.001. Graphs are pooled from at least three independent experiments performed in duplicate.
Error bars represent the standard error of the mean.
Figure 3.2: MAb-E2 binding kinetics are not altered by changes in temperature. AB.

SPR analysis of MAb binding to soluble E2 at different temperatures.

Examples of

sensograms (inset) and graphs of the steady-state fit of E2 binding to H77.39 at 4°C (A) and
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37°C (B) are shown. Points represent maximum resonance units (RU) at various concentrations
of E2 and the solid line represents the steady-state fit of the maximim RU values. C. Effect of time
o

of incubation at 4 C on MAb neutralization. MAbs (50 µg/ml of H77.39, J6.36, anti-CD81 (positive
control) and WNV-E16 (negative control) were incubated with J6/JFH1/Jc1 luciferase reporter
virus at 4°C for one hour and added directly to Huh7.5 cells (T=0, white bars), or incubated for an
o

additional 12 (T=12, black bars) or 24 hours (T=24, grey bars) at 4 C prior to infection. Cells were
infected for one hour at 4°C, washed at 4°C to remove unbound virus, the temperature was
raised to 37°C, and infectivity detected by luciferase assay 48 hours later. Infectivity is displayed
relative to conditions in the absence of MAb. Graphs are pooled from three independent
experiments performed in duplicate. Asterisks represent statistically significant differences in
infectivity compared to cells infected in the absence of antibody at the specified time point: *, P <
o

0.05; **, P < 0.01; and ***, P < 0.001. D. Effect of time of incubation at 4 C on infectivity in the
absence of MAb. J6/JFH1/Jc1 luciferase reporter virus was incubated at 4°C for one hour (T=0)
or an additional 12 (T=12) or 24 hours (T=24). Infectivity is expressed as relative light units
(RLU). Data are pooled from three independent experiments performed in triplicate. Infectivity is
not significantly different at T=12 and T=24 compared to T=0. Error bars represent the standard
error of the mean.
Figure 3.3: Changes in temperature alter MAb-virus binding. J6/JFH1/Jc1 luciferase
reporter virus was pre-incubated for one hour at 4°C (white bars), 37°C (grey bars), or 40°C
(black bars) with J6.36 MAb, a negative control MAb (WNV-E16) or medium alone, precipitated
with protein G Sepharose beads, and the quantity of virus was assessed by qRT-PCR. Data are
pooled from at least three independent experiments performed in duplicate. Fold change is
calculated compared to viral RNA detected in the absence of antibody. Asterisks represent
statistically significant differences: *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Error bars
represent the standard error of the mean.
Figure 3.4: Incubation time alters MAb neutralization and binding to HCV. A-D.
Neutralization analysis. Serial dilutions of (A) H77.39 or (B) J6.36 were incubated with

	
  

99
	
  

J6/JFH1/Jc1 luciferase reporter virus for one hour at 37°C to achieve a baseline equilibrium.
Samples were added either immediately to Huh7.5 cells (time 0,) or incubated for an additional
2 (T=2,☐), 4 (T=4,Δ), or 8 (T=8, ●) hours at 37°C prior to infection of cells. Infectivity was
determined by luciferase expression 48 hours later. Dose response curves are statistically
different (F-test, P < 0.0001) and are displayed relative to the infectivity of HCV incubated for the
indicated time interval in the absence of MAb. EC50 values of (C) H77.39 and (D) J6.36 at each
time point were determined by non-linear regression analysis. Asterisks represent significant
differences in EC50 values compared to T=0: *, P < 0.05; **, P < 0.01; and ***, P < 0.001. E.
Immunoprecipitation assays. J6.36 and J6/JFH1/Jc1 virus were pre-incubated for one hour at
37°C to achieve baseline equilibrium binding. Protein G Sepharose beads were added
immediately (T=0) or at 2, 4, and 8 hours (T=2, 4 and 8, respectively) and bound virus was
quantitated by qRT-PCR. Fold change was determined compared to background binding of virus
to beads alone. Asterisks represent significant differences in fold change in virus precipitated at
T=0 compared to other times: *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Graphs are pooled
from at least three independent experiments performed in duplicate and error bars represent the
standard error of the mean.
Figure 3.5: The effects of increased incubation time and temperature on additional
neutralizing and non-neutralizing MAbs. Serial dilutions of additional purified (A) strongly, (B)
weakly, or (C) non-neutralizing MAbs were incubated with either J6/JFH1/Jc1 reporter virus
(J6.103) or H77/JFH1 virus (H77.16, H77.31, H77.46, J6.27) for one hour at 37°C or 40°C. VirusMAb mixtures were then immediately added to cells (T=0) or incubated for an additional 12 hours
(T=12) at 37°C prior to infection of cells. Dose response curves are displayed relative to the
infectivity of HCV in the absence of antibody for each of the conditions tested and represented by
the following symbols: , T=0 h, 37°C; , T=0 h, 40°C; , T=12 h, 37°C. Graphs are pooled
from at least three independent experiments performed in duplicate. Error bars represent the
standard error of the mean. Asterisks represent significant differences in the EC50 value
compared to that at time 0, 37°C: *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
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Figure 3.6: Kinetic and temperature-dependent enhancement of neutralization by
sera from HCV infected patients. A. Chronic phase sera from HCV infected patients (H06, AA)
or control sera (SM) was serially diluted and incubated with genotype 2a J6/JFH1/Jc1 luciferase
reporter virus for one hour at 37°C or 40°C. Sera-virus complexes were then added directly to
Huh7.5 cell monolayers (T=0) or incubated for an additional 12 hours at 37°C prior to infection of
cells (T=12). Infectivity was assessed by luciferase expression 48 hours post-infection.
Comparison of dose response curves by F test demonstrated a significant difference (P < 0.0001)
in neutralization under different conditions by H06 and AA, but not by negative control sera (SM).
B. Acute or chronic phase sera from HCV infected patients (S154, S112, S18 and S19) or control
sera (SM) was serially diluted and incubated with H77/JFH1 chimeric virus for one hour at 37°C
or 40°C. Sera-virus complexes were added to pre-seeded Huh7.5 cells (T=0) or incubated for an
additional 12 hours at 37°C prior to infection of cells (T=12). Infectivity was assessed by FFU
assay 72 hours post-infection. Comparison of dose response curves by F test demonstrated a
significant difference (P < 0.0001) in neutralization under different conditions with S154, S112,
S18 and S19 sera, but not with negative control serum (SM). Dose response curves are
displayed relative to the infectivity of HCV in the absence of antibody for each of the conditions
tested and represented by the following symbols: , T=0 h, 37°C; , T=0 h, 40°C; , T=12 h,
37°C. Graphs are pooled from at least three independent experiments performed in duplicate and
error bars represent the standard error of the mean.
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Table 3.1. Kinetic parameters of MAb binding to sE2 at different temperatures
KD (4°C)
H77.39-H77 E2 (1a)

1.66x10

-7

H77.39-J6 E2 (2a)

2.50x10

-7

4.25x10

-8

J36-J6 E2 (2a)

	
  

KD (37°C)

102
	
  

Fold difference

4.69x10

-8

3.54

4.84x10

-8

5.17

8.91x10

-9

4.77
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ABSTRACT
Although MAbs directed against HCV-E2 have been described previously (see Table 1,
Chapter 1), analysis has been limited by a restricted culture system, the lack of an E2 crystal
structure, and the absence of a tractable small animal model. In particular, the study of antibody
neutralization largely have been limited to a single replicating strain or HCVpp, and extensive
studies of pre- and post-attachment inhibition have not been performed. Furthermore, mapping
of critical binding residues has been performed largely by site-directed alanine mutagenesis,
which precludes the discovery of novel or conformational epitopes. In this thesis, we have
generated a large panel of mouse anti-E2 MAbs, characterized their neutralizing capabilities, and
mapped their critical binding residues using a novel library of E2 variants displayed on the surface
of yeast. These studies have led to an enhanced understanding of the mechanics of antibodymediated neutralization of HCV, as well as the structure of E2. An in depth analysis of these
advances, as well as potential future studies, are discussed in the following sections.
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Anti-E2 MAbs neutralize at both pre- and post-attachment steps
HCV entry is a complex process, requiring multiple attachment factors and receptors
(11). In theory, neutralizing MAbs may block at one of several steps during and after viral
attachment, yet few studies of post-attachment neutralization have been performed. Studies with
distantly related flaviviruses suggest that MAbs inhibiting at a post-attachment step are highly
potent, possibly due to the lower occupancy requirement required by these to MAbs block key
entry steps (44). We hypothesized that identification of HCV-specific MAbs that neutralized at a
post-attachment step, and mapping of their critical binding residues, would provide new insight
that could inform future vaccine or therapeutic antibody development. Here, I identified three
MAbs against HCV E2 (H77.16, H77.39 and J6.36), which neutralize at a post-attachment step.
All three MAbs mapped to regions near or within the HVR1, suggesting that the HVR1 remains
accessible after viral attachment and that MAbs that bind to this region can disrupt later steps in
the entry pathway.
Post-attachment neutralization of HCV may prevent fusion or other requisite receptor
interactions after attachment. Indeed, anti-SR-B1 and anti-CD81 antibodies inhibit infection after
viral attachment to hepatocytes (3, 6, 18, 25, 56), thus suggesting two possible post-attachment
steps at which HCV entry can be blocked. Coupled with antibody mapping data, determination of
the mechanism of neutralization would aid in dissecting the precise steps of HCV entry and the
critical E2 epitopes required for infection. To distinguish MAbs that prevent viral fusion from those
that block earlier steps in viral entry, an attachment and entry assay with labeled MAbs could be
performed as described in Thompson et al (50). In brief, virus is pre-bound to cells at 4°C,
fluorescently labeled MAbs are subsequently added, the temperature is raised to 37°C to allow
entry, and cells are assessed by fluorescence confocal microscopy. MAbs that inhibit viral fusion
will be visualized intracellularly, whereas those that block infection at a post-attachment step but
prior to entry will remain bound to virus on the cell surface. Alternatively, purified virus can be
labeled directly with fluorescent dye, as described for other flaviviruses(36), which would allow for
direct tracking of the virus in the presence and absence of MAb.
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If no MAbs that prevent viral fusion directly were identified in our panel, it may be
necessary to generate additional MAbs for further study. One limit to our panel is that MAbs were
generated and screened against sE2 and not infectious virus. Although successful, such an
approach might limit the detection of conformational epitopes expressed only on whole virus;
indeed, some MAbs that neutralize potently at a post-attachment step and recognize
conformational epitopes exclusively on the virion and not on soluble West Nile Virus E protein
have been identified (55). Thus, identification of novel epitopes utilized in viral entry and fusion
might require further generation of MAbs against conformational forms of HCV.

One such

approach, described below, would involve generating B cell hybridomas from the lymphocytes of
HCV infected patients and screening for MAbs by either viral trap ELISA or by neutralization
assay.

Neutralizing MAbs block binding to CD81 and SR-B1
Although SR-B1 is well recognized as an HCV co-receptor (47), prior to our studies only
one MAb, 9/27, had been shown to inhibit sE2-SR-B1 interactions (2, 47). Here, we identify five
MAbs (H77.16, H77.31, H77.39, J6.36 and J6.103) that inhibit sE2 binding to SR-B1 by varying
degrees; furthermore, three of these (H77.31, H77.39 and J6.36) also inhibited E2 binding to
CD81, suggesting the CD81 binding region and HVR1 are in close proximity. Interestingly, the
most potent inhibitor of sE2 binding to SR-B1 and CD81, H77.39, mapped to residues outside
both the HVR1 and the CD81 binding motif (e.g., residues N415 and N417) (42). The ability of
H77.39 to inhibit post-attachment binding to two HCV co-receptors, suggests the discovery of an
“Achilles heel” for HCV. Although the CD81 binding domain is well protected (1, 20), H77.39
subverts these protective mechanisms by localizing to less shielded residues that are not directly
involved in CD81 binding, yet still allow for antibody-mediated inhibition of CD81 binding. It is
tempting to speculate that viral escape from H77.39 would be difficult due to i) the level of
conservation of residues N415 and N417 between genotypes(19, 42); ii) poor viral fitness of cell
culture viruses harboring mutations at N415(14); iii) my data demonstrating that H77.39 blocks
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two HCV co-receptors, possibly limiting the ability of the virus to escape by altering receptor
usage(21). Generation and assessment of variants resistant to H77.39 neutralization, however,
will be necessary to begin to address these hypotheses.
One caveat to our receptor binding studies is they assess receptor interactions with sE2,
rather than whole virus. E2 likely exists in close association with E1 on the viral surface (53), and
receptor binding sites may be exposed differently on the virion compared to sE2. Indeed, we did
not observe sE2 binding to CLDN-1 and OCLN in our unpublished studies, suggesting that both
receptors may bind either conformational epitopes or alternate, surface exposed viral proteins.
Indeed, a recent study demonstrating that OCLN could immunoprecipitate components of whole
virus suggests that OCLN interactions require whole virus(32). To overcome these limitations, a
receptor-binding assay using infectious virus or HCVpp will need to be developed. Attempts in
our lab to study HCV-receptor binding utilized CHO cells expressing CD81, SR-B1, CLDN-1 or
OCLN.

Unfortunately, high levels of background binding of HCV to WT CHO cells made

interpretation of the results of these assays challenging. Although sE2 displays no background
binding to WT CHO (27, 46), HCV virus is known to associate with apolipoproteins and other
serum components (34, 40) that may result in non-specific adsorption to CHO cells. Reduction of
background may require identification of a cell line that shows less non-specific interaction with
virus.

Neutralization of infectious HCV representative of multiple genotypes
HCV is highly divergent between genotypes, particularly in the HVR1 (48), as a result of
it’s error prone polymerase, chronic infection, geographic distribution, and high rate of replication
(9, 35).

Identification of target residues conserved between genotypes will be important in

informing the design of novel therapeutics that could be directed at multiple HCV genotypes. To
screen for MAbs with cross-binding capacity, we expressed E2 representative of all six HCV
genotypes on the surface of yeast and screened for MAb binding by flow cytometry. Only 13
MAbs bound E2 derived from all six HCV genotypes, of which only 2 neutralized infectious virus,
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suggesting that the conserved epitopes recognized by the other 11 MAbs are either not involved
in viral entry or poorly accessible on the surface of the virion.
Of the two neutralizing MAbs with broad cross-binding potential, only H77.39 neutralized
HCV strains representative of multiple genotypes. Until recently, only one strain of HCV (JFH1,
genotype 2a) (31) had been successfully propagated in cell culture, and analysis of MAb
neutralization of different genotypes was limited to HCVpp (4, 22, 28, 41, 43, 49), which are not
believed to recapitulate the structural characteristics of infectious HCV(38, 53). To our
knowledge, H77.39 is the first described MAb that neutralizes replicating virus representative of
five out of six HCV genotypes. MAb H77.39 neutralized infection of chimeric viruses expressing
structural proteins of genotypes 1, 2, 3, 4 and 5 in a dose-dependent manner, suggesting that the
residues to which H77.39 maps (N415 and N417) are conserved and accessible on all
genotypes. H77.39 did not neutralize chimeric virus representative of genotype 6, however this
may be explained by the presence of a mutation at residue N417, which was necessary for cell
culture adaptation(17), but is rarely observed in clinical isolates(19, 42).
As described above, H77.39 potently neutralizes at a post-attachment step and inhibits
binding to SR-B1 and CD81. Furthermore mutation of its binding residue (N417) impairs viral
fitness(14). Based on these findings, the H77.39 epitope would seem an excellent target for the
host immune response. Interestingly, all previously characterized MAbs that localize to residue
N417 were generated in mice (H77.39, AP33) or rats (3/11), raising the possibility that this
epitope is not targeted or at best, sub-dominant in the human immune response. Indeed, previous
studies with WNV demonstrate that the murine humoral response generates highly neutralizing
antibodies targeted to the DIII lateral ridge epitope, whereas the human response produces less
inhibitory antibodies that recognize the DII fusion loop(37); whether there are differences in
epitope targeting of HCV between mouse and human remains to be explored. Interestingly, none
of the published neutralizing MAbs generated from human lymphocytes map to residues N417
(see Table 4 in chapter 2 or in (46)), although to date too few human MAbs have been studied to
draw general conclusions about the human humoral response to E2, and further studies are
warranted.
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One difficulty in studying the human antibody response in general has been the inability
to generate stable human lymphocyte hybridomas. Instead, two alternative approaches have
been used with other pathogens(5, 51): phage display of Fab fragments or EBV transformation of
memory B cells and/or plasmablasts. Recently, however, an efficient novel fusion partner for
human lymphocytes derived from either peripheral blood or lymph nodes has been described
(23).

In collaboration with the Trakht laboratory at Columbia University, we have identified

several strongly neutralizing human MAbs against HCV (data not shown). In future studies, the
Trakht and Diamond laboratories plans to characterize anti-E2 human MAbs generated from the
lymphocytes of intravenous drug users (IDUs) who rapidly clear infection and have strong and
broadly cross-neutralizing serum antibody responses (7, 39).

Mapping of neutralizing MAbs provides novel insights into the structure of E2
A major limitation in the study of neutralizing MAb-HCV interactions is the lack of an
atomic resolution structure of E1, E2, or E1-E2. Previous mapping studies of anti-E2 MAbs
utilized an ELISA-based peptide mapping approach (4, 12) or alanine scanning of recombinant
E1E2 by ELISA (22, 28, 43, 49). Although useful for some MAbs, this method is most effective
for a subset of antibodies that bind linear determinants. Furthermore, there is also a concern that
the structure that short peptides adopt in solution or the solid phase may not reflect the structure
of a more complex domain or intact protein. Finally, these studies rely on alanine scanning and
thus, are biased in the selection of potential mutants. In the studies described in my thesis, I
utilized a novel, unbiased mapping strategy in which random mutations were introduced into
recombinant E2 displayed via a linker on the surface of yeast and loss of binding mutants were
identified by flow cytometry. Using this strategy we identified two neutralizing MAbs, H77.16 and
J6.36, which map to residues over 150 amino acid residues apart; H77.16 maps to residues in
the HVR1 (G406, N410, I411) and the putative CD81 binding region (G530) and J6.36 maps to
the HVR1 (G397, F403, G406) as well as residue R572. In the context of a recently proposed
model of E2 (26), this mapping data suggests that the HVR1, which is predicted to be an
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unstructured extension of DI, actually lies between the putative D1 and DIII in the conformational
virion. Localization of the HVR1 between DI and DIII, both of which contain portions of the CD81
binding motif, also supports previous studies suggesting that the CD81 binding region is obscured
by the HVR1 (1).
A major limitation to our mapping strategy is that E2 is expressed on the yeast in the
absence of E1. E1 and E2 are predicted to form a heterodimer and be tightly linked on the viral
surface (53), although the conformation of these proteins as a heterodimer is unknown.
Discovery of MAbs that map to residues within both proteins would provide insight into the
structure of E1-E2 as well as allow for the identification of novel epitopes. Mapping could be
performed by generation of viral escape mutants, which would also allow for the identification of
conformational epitopes.
Generation of viral escape mutants also could provide important information regarding
the mechanism of viral escape from immune pressure. Recent studies with influenza have
demonstrated that viral escape can be mediated by changes in receptor affinity resulting from
mutations distant to the MAb binding site, such that MAb binding is preserved but neutralization is
lost (21). Given its requirement for multiple receptors, it is possible that HCV can escape immune
pressure by mutating amino acid residues that alter receptor usage. Indeed, although HCV is
initially attenuated in HVR1 deletion mutants, titers eventually rise suggesting the incorporation of
adaptive mutations that compensate for the inability to interact with SR-B1 (13, 45). To directly
address whether HCV can evade antibody neutralization by altering receptor usage, escape
mutants could be made with different MAbs. Mutations that result in loss of neutralization could
then be cloned into E2 and MAb binding to the E2 variants assessed. Mutations that result in a
loss of MAb neutralization yet retain binding to the complementing mutant E2 protein would
suggest that viral escape was due to mutations that did not directly alter MAb binding. Testing for
changes in receptor binding and affinity could then be used to assess the mechanism of escape
by variants of interest.
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Exposure of E2 epitopes and neutralization is altered by changes in temperature
Antibody neutralization of flaviviruses is governed by both MAb affinity and epitope
availability (10, 24). Although it would be predicted that epitopes hidden in the conformational
structure of the virus would not be sufficiently available for neutralization, multiple studies with
both enveloped and non-enveloped viruses have suggested that cryptic epitopes can become
transiently exposed, suggesting that viral particles are in constant, dynamic motion (8, 29, 30,
33). Recent studies with flaviviruses demonstrate that increasing pre-incubation time and
temperature enhances exposure of obscured epitopes, resulting in improved MAb function (8,
33). Although a member of the Flaviviridae, HCV has unique properties that could limit viral
movement, including 15 predicted N-linked glycosylation sites on E1 and E2 (15, 16), 9
intramolecular disulfide bonds (26), and covalent interactions between E1 and E2 (53). In these
studies, we demonstrate that, despite these constraints, antibody neutralization of HCV is
enhanced when pre-incubation time and temperature are increased, suggesting that HCV does
undergo some degree of dynamic motion or changes in conformation akin to those described for
flaviviruses (8, 33). Interestingly, two anti-HCV E2 MAbs, H77.31 and J6.27, which map to a
linear epitope in the CD81 binding region, did not demonstrate enhanced neutralizing capability
under any conditions tested, suggesting that a conformational change, rather than small transient
movements, are involved in exposure the CD81 binding site. Indeed, Tscherne et al have
demonstrated that HCV can only undergo “fusion from without” after prior binding to the target
cell, suggesting that HCV undergoes significant conformational changes during attachment and
entry (52). Cryo-EM studies and resolution of the envelope glycoprotein crystal structures will be
critical in proving these hypotheses.
We confirmed that increased pre-incubation time and temperature enhanced the
neutralizing capabilities of acute and chronic phase sera from HCV infected patients, suggesting
that the time spent circulating in the bloodstream prior to productive infection, as well as the
presence or absence of fever, may modulate the potency of the humoral response in vivo.
Whether this can be extrapolated to other viruses or to in vivo models remains to be tested,
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although it is tempting to speculate that one function of fever (which also can be induced by
interferon-α treatment) (57) is to enhance the effectiveness of the MAb response. Furthermore,
these results suggest that in vitro neutralization studies may not be entirely predictive of antibody
efficacy in vivo. Indeed, previous studies in our laboratory have demonstrated that effector
functions significantly modulate in vivo protection of antibodies (54).
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